1775 lines
282 KiB
Text
1775 lines
282 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK585274">
|
|
<meta name="ncbi_domain" content="niceng220er4">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK585274/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence review for the pharmacologicalmanagement of fatigue - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence review for the pharmacologicalmanagement of fatigue - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="author" content="Guideline Updates Team (UK)">
|
|
<meta name="citation_title" content="Evidence review for the pharmacologicalmanagement of fatigue">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2022/06">
|
|
<meta name="citation_author" content="Guideline Updates Team (UK)">
|
|
<meta name="citation_pmid" content="36279388">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK585274/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence review for the pharmacologicalmanagement of fatigue">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Contributor" content="Guideline Updates Team (UK)">
|
|
<meta name="DC.Date" content="2022/06">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK585274/">
|
|
<meta name="og:title" content="Evidence review for the pharmacologicalmanagement of fatigue">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK585274/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng220er4-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng220er4/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK585274/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D12C17D6D23010000000001370103.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK585274/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK585274/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK585274/&text=Evidence%20review%20for%20the%20pharmacologicalmanagement%20of%20fatigue"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK585274/?report=classic">Switch to classic view</a><a href="/books/n/niceng220er4/pdf/">PDF (2.4M)</a><a href="/books/n/niceng220er4/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK585274%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D12C17D6D23010000000001370103.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng220er4-lrg.png" alt="Cover of Evidence review for the pharmacologicalmanagement of fatigue" /></a></div><div class="bkr_bib"><h1 id="_NBK585274_"><span itemprop="name">Evidence review for the pharmacologicalmanagement of fatigue</span></h1><div class="subtitle">Multiple sclerosis in adults: management</div><p><b>Evidence review D</b></p><p><i>NICE Guideline, No. 220</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Guideline Updates Team (UK)</span>.</p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2022 Jun</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-4607-5</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2022.</div></div><div class="bkr_clear"></div></div><div id="niceng220er4.s1"><h2 id="_niceng220er4_s1_">1. Pharmacological management of fatigue</h2><div id="niceng220er4.s1.1"><h3>1.1. Review question</h3><p>For adults with MS, including people receiving palliative care, what is the clinical and cost effectiveness of pharmacological interventions for fatigue?</p><div id="niceng220er4.s1.1.1"><h4>1.1.1. Introduction</h4><p>Fatigue is thought to be the commonest and one of the most debilitating symptoms of multiple sclerosis. It can affect up to 80% of the MS population. Causes can be multifactorial with both physical and cognitive implications. There are recognised associations with heat, overexertion, stress or maybe the time of the day. The symptoms appear completely out of proportion to prior activity levels.</p><p>Fatigue is a universal experience; it is a self-recognised phenomenon that is subjective in nature. It is a common symptom in the general population and can be caused by a variety of medical problems such as anaemia or thyroid disease. Amantadine is available to treat fatigue in people with MS – but the mechanism of action, risks or benefits are unclear and have not been quantified. If trialled, medication such as amantadine found to directly help fatigue only benefits a proportion of MS sufferers and does not always eliminate the problem altogether. In addition to fatigue being a primary symptom of MS, some medication to control other MS symptoms may cause drowsiness and exacerbate underlying fatigue further.</p><p>There is no clear pharmacological management and therefore possible disparity in practice. New treatments may be available to help treat and manage fatigue in MS.</p></div><div id="niceng220er4.s1.1.2"><h4>1.1.2. Summary of the protocol</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab1"><a href="/books/NBK585274/table/niceng220er4.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab1" rid-ob="figobniceng220er4tab1"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab1/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab1/?report=previmg" alt="Table 1. PICO characteristics of review question." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab1"><a href="/books/NBK585274/table/niceng220er4.tab1/?report=objectonly" target="object" rid-ob="figobniceng220er4tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div><p>For full details see the review protocol in <a href="#niceng220er4.appa">Appendix A</a>.</p></div><div id="niceng220er4.s1.1.3"><h4>1.1.3. Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>. Methods specific to this review question are described in the review protocol in <a href="#niceng220er4.appa">appendix A</a> and the methods document. Declarations of interest were recorded according to <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s conflicts of interest policy</a>.</p></div><div id="niceng220er4.s1.1.4"><h4>1.1.4. Effectiveness evidence</h4><div id="niceng220er4.s1.1.4.1"><h5>1.1.4.1. Included studies</h5><p>Seventeen randomised controlled trial studies (from twenty-one papers) were included in the review;<a class="bibr" href="#niceng220er4.s1.1.ref1" rid="niceng220er4.s1.1.ref1"><sup>1</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref2" rid="niceng220er4.s1.1.ref2"><sup>2</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref4" rid="niceng220er4.s1.1.ref4"><sup>4</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref7" rid="niceng220er4.s1.1.ref7"><sup>7</sup></a><sup>–</sup><a class="bibr" href="#niceng220er4.s1.1.ref10" rid="niceng220er4.s1.1.ref10"><sup>10</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref12" rid="niceng220er4.s1.1.ref12"><sup>12</sup></a><sup>–</sup><a class="bibr" href="#niceng220er4.s1.1.ref16" rid="niceng220er4.s1.1.ref16"><sup>16</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref19" rid="niceng220er4.s1.1.ref19"><sup>19</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref22" rid="niceng220er4.s1.1.ref22"><sup>22</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref24" rid="niceng220er4.s1.1.ref24"><sup>24</sup></a><sup>–</sup><a class="bibr" href="#niceng220er4.s1.1.ref26" rid="niceng220er4.s1.1.ref26"><sup>26</sup></a> these are summarised in <a class="figpopup" href="/books/NBK585274/table/niceng220er4.tab2/?report=objectonly" target="object" rid-figpopup="figniceng220er4tab2" rid-ob="figobniceng220er4tab2">Table 2</a> below. These studies included 12 parallel trials;<a class="bibr" href="#niceng220er4.s1.1.ref2" rid="niceng220er4.s1.1.ref2"><sup>2</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref4" rid="niceng220er4.s1.1.ref4"><sup>4</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref7" rid="niceng220er4.s1.1.ref7"><sup>7</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref9" rid="niceng220er4.s1.1.ref9"><sup>9</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref10" rid="niceng220er4.s1.1.ref10"><sup>10</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref12" rid="niceng220er4.s1.1.ref12"><sup>12</sup></a><sup>–</sup><a class="bibr" href="#niceng220er4.s1.1.ref15" rid="niceng220er4.s1.1.ref15"><sup>15</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref22" rid="niceng220er4.s1.1.ref22"><sup>22</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref24" rid="niceng220er4.s1.1.ref24"><sup>24</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref26" rid="niceng220er4.s1.1.ref26"><sup>26</sup></a> and 5 crossover trials<a class="bibr" href="#niceng220er4.s1.1.ref1" rid="niceng220er4.s1.1.ref1"><sup>1</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref8" rid="niceng220er4.s1.1.ref8"><sup>8</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref16" rid="niceng220er4.s1.1.ref16"><sup>16</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref19" rid="niceng220er4.s1.1.ref19"><sup>19</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref25" rid="niceng220er4.s1.1.ref25"><sup>25</sup></a>. Evidence from these studies is summarised in the clinical evidence summary below (<a class="figpopup" href="/books/NBK585274/table/niceng220er4.tab3/?report=objectonly" target="object" rid-figpopup="figniceng220er4tab3" rid-ob="figobniceng220er4tab3">Table 3</a>).</p><p>These studies include the following comparisons:
|
|
<ul><li class="half_rhythm"><div>Amantadine compared to aspirin<a class="bibr" href="#niceng220er4.s1.1.ref25" rid="niceng220er4.s1.1.ref25"><sup>25</sup></a></div></li><li class="half_rhythm"><div>Amantadine compared to modafinil<a class="bibr" href="#niceng220er4.s1.1.ref14" rid="niceng220er4.s1.1.ref14"><sup>14</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref19" rid="niceng220er4.s1.1.ref19"><sup>19</sup></a></div></li><li class="half_rhythm"><div>Amantadine compared to placebo<a class="bibr" href="#niceng220er4.s1.1.ref1" rid="niceng220er4.s1.1.ref1"><sup>1</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref2" rid="niceng220er4.s1.1.ref2"><sup>2</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref8" rid="niceng220er4.s1.1.ref8"><sup>8</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref13" rid="niceng220er4.s1.1.ref13"><sup>13</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref14" rid="niceng220er4.s1.1.ref14"><sup>14</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref16" rid="niceng220er4.s1.1.ref16"><sup>16</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref19" rid="niceng220er4.s1.1.ref19"><sup>19</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref22" rid="niceng220er4.s1.1.ref22"><sup>22</sup></a></div></li><li class="half_rhythm"><div>SSRIs compared to placebo (analysed as a class, the formulations included are):
|
|
<ul class="circle"><li class="half_rhythm"><div>Fluoxetine compared to placebo<a class="bibr" href="#niceng220er4.s1.1.ref4" rid="niceng220er4.s1.1.ref4"><sup>4</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref7" rid="niceng220er4.s1.1.ref7"><sup>7</sup></a></div></li><li class="half_rhythm"><div>Paroxetine compares to placebo<a class="bibr" href="#niceng220er4.s1.1.ref9" rid="niceng220er4.s1.1.ref9"><sup>9</sup></a></div></li></ul></div></li><li class="half_rhythm"><div>Aspirin compared to placebo<a class="bibr" href="#niceng220er4.s1.1.ref24" rid="niceng220er4.s1.1.ref24"><sup>24</sup></a></div></li><li class="half_rhythm"><div>Modafinil compared to placebo<a class="bibr" href="#niceng220er4.s1.1.ref10" rid="niceng220er4.s1.1.ref10"><sup>10</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref14" rid="niceng220er4.s1.1.ref14"><sup>14</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref15" rid="niceng220er4.s1.1.ref15"><sup>15</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref19" rid="niceng220er4.s1.1.ref19"><sup>19</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref26" rid="niceng220er4.s1.1.ref26"><sup>26</sup></a></div></li><li class="half_rhythm"><div>Combination of pharmacological therapies (amantadine and aspirin) compared to amantadine<a class="bibr" href="#niceng220er4.s1.1.ref12" rid="niceng220er4.s1.1.ref12"><sup>12</sup></a></div></li></ul></p><p>No relevant clinical studies comparing any intervention with usual care were identified. There was limited evidence comparing active treatments to each other and comparing combinations of treatments to other treatments and placebo. No studies reported the following outcomes:
|
|
<ul><li class="half_rhythm"><div>Visual Analogue Scale (VAS) measure of fatigue</div></li><li class="half_rhythm"><div>Impact on patients/carers</div></li></ul></p><p>All studies used oral preparations and conventional doses of the study medication. The majority of outcomes were reported at less than 3 months. These outcomes were included in the review but downgraded for outcome indirectness as they did not fulfil a period of 3–6 months as stated in the protocol (see indirectness section for further information).</p><div id="niceng220er4.s1.1.4.1.1"><h5>Inconsistency</h5><p>Two outcomes had significant statistical heterogeneity (I<sup>2</sup> >50%). In both cases, the meta-analysis included two or three studies and so there was insufficient data to populate subgroups to complete a subgroup analysis. These outcomes were therefore analysed using a random effects model and were downgraded for inconsistency.</p></div><div id="niceng220er4.s1.1.4.1.2"><h5>Indirectness</h5><p>The majority of outcomes in this review were downgraded for indirectness. This was due to one of two reasons:
|
|
<ul><li class="half_rhythm"><div>Outcome indirectness – the majority of studies had less than 3 months follow up.</div></li><li class="half_rhythm"><div>Population indirectness – one study<a class="bibr" href="#niceng220er4.s1.1.ref9" rid="niceng220er4.s1.1.ref9"><sup>9</sup></a> included participants with multiple sclerosis and major depressive disorder. As fatigue can be a symptom of both conditions, this was considered as a source of indirectness.</div></li></ul></p></div><div id="niceng220er4.s1.1.4.1.3"><h5>Meta-analysis</h5><p>Studies reported continuous outcomes in various ways across and within studies. For example, within a single study the same protocol outcome category could be reported in multiple scales that are not comparable (such as cognitive functions where, the symbol digit modalities test could be reported in the same study as the California verbal learning test-II).</p><p>In these cases, all forms of the outcome have been extracted and pooled with other studies reporting outcomes in the same scale.</p><p>All studies reported final values. Where possible, parallel and crossover trials have been combined (using generic inverse variance analysis as appropriate).</p></div><div id="niceng220er4.s1.1.4.1.4"><h5>Studies not using pharmacological interventions specifically for fatigue</h5><p>Four studies did not specifically use pharmacological interventions to manage fatigue. In these studies, the agents were either used for neuroprotection (Cambron 2016<a class="bibr" href="#niceng220er4.s1.1.ref5" rid="niceng220er4.s1.1.ref5"><sup>5</sup></a>, Chataway 2020<a class="bibr" href="#niceng220er4.s1.1.ref7" rid="niceng220er4.s1.1.ref7"><sup>7</sup></a>), depression (Ehde 2008<a class="bibr" href="#niceng220er4.s1.1.ref9" rid="niceng220er4.s1.1.ref9"><sup>9</sup></a>) or for cognitive function (Ford-Johnson 2016<a class="bibr" href="#niceng220er4.s1.1.ref10" rid="niceng220er4.s1.1.ref10"><sup>10</sup></a>). These studies were included in the review as they also investigated the effect on fatigue.</p></div><div id="niceng220er4.s1.1.4.1.5"><h5>Previously included studies and outcomes</h5><p>All studies included in the previous version of the guideline were included in this updated version of the review. However, four studies that were published before 2014 but were not included in the previous version of the guideline were included in this review (Ashtari 2009<a class="bibr" href="#niceng220er4.s1.1.ref2" rid="niceng220er4.s1.1.ref2"><sup>2</sup></a>, Hamzei-Moghaddam 2011<a class="bibr" href="#niceng220er4.s1.1.ref12" rid="niceng220er4.s1.1.ref12"><sup>12</sup></a>, Möller 2011<a class="bibr" href="#niceng220er4.s1.1.ref15" rid="niceng220er4.s1.1.ref15"><sup>15</sup></a> and Stankoff 2005<a class="bibr" href="#niceng220er4.s1.1.ref26" rid="niceng220er4.s1.1.ref26"><sup>26</sup></a>). For Moghaddam 2011<a class="bibr" href="#niceng220er4.s1.1.ref12" rid="niceng220er4.s1.1.ref12"><sup>12</sup></a>, Möller 2011<a class="bibr" href="#niceng220er4.s1.1.ref15" rid="niceng220er4.s1.1.ref15"><sup>15</sup></a> and Stankoff 2005<a class="bibr" href="#niceng220er4.s1.1.ref26" rid="niceng220er4.s1.1.ref26"><sup>26</sup></a>, this is because they included interventions that were excluded in the previous version of the guideline (combinations of treatments and modafinil respectively) but were relevant to the current review protocol. For Ashtari 2009<a class="bibr" href="#niceng220er4.s1.1.ref2" rid="niceng220er4.s1.1.ref2"><sup>2</sup></a>, it is unclear why it was not identified as part of the previous version of this review. A fifth study fulfilled the inclusion criteria but was not included in the previous version of the guideline (Rosenberg 1988<a class="bibr" href="#niceng220er4.s1.1.ref23" rid="niceng220er4.s1.1.ref23"><sup>23</sup></a>). This study was not included as it was a small study (n=10) from before the date limitation which was unlikely to add sufficient data to impact the recommendations from this review. In studies that were previously included in the guideline, some outcomes were not included in analyses. This was either because the outcomes reported in the paper did not fall into categories stated in protocol (such as reporting total adverse events) or because the outcomes were reported in a way where meta-analysis would not be possible and would make interpretation difficult.</p><p>See also the study selection flow chart in <a href="#niceng220er4.appc">Appendix C</a>, study evidence tables in <a href="#niceng220er4.appd">Appendix D</a>, forest plots in <a href="#niceng220er4.appe">Appendix E</a> and GRADE tables in <a href="#niceng220er4.appf">Appendix F</a>.</p></div></div><div id="niceng220er4.s1.1.4.2"><h5>1.1.4.2. Excluded studies</h5><p>Of the thirty-two papers excluded from the review after reviewing full texts, this included two Cochrane reviews. These reviews were excluded either because of incorrect population (post-stroke fatigue)<a class="bibr" href="#niceng220er4.s1.1.ref27" rid="niceng220er4.s1.1.ref27"><sup>27</sup></a> or because the systematic review was withdrawn by the Cochrane and PaPaS review group as it did not meet their timelines and expectations<a class="bibr" href="#niceng220er4.s1.1.ref21" rid="niceng220er4.s1.1.ref21"><sup>21</sup></a>.</p><p>See the excluded studies list in <a href="#niceng220er4.appj">Appendix J</a>.</p></div></div><div id="niceng220er4.s1.1.5"><h4>1.1.5. Summary of studies included in the effectiveness evidence</h4><div id="niceng220er4.s1.1.5.1"><h5>1.1.5.1. Amantadine compared to aspirin</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab2"><a href="/books/NBK585274/table/niceng220er4.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab2" rid-ob="figobniceng220er4tab2"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab2/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab2/?report=previmg" alt="Table 2. Summary of studies included in the evidence review." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab2"><a href="/books/NBK585274/table/niceng220er4.tab2/?report=objectonly" target="object" rid-ob="figobniceng220er4tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div></div><div id="niceng220er4.s1.1.5.2"><h5>1.1.5.2. Amantadine compared to modafinil</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab3"><a href="/books/NBK585274/table/niceng220er4.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab3" rid-ob="figobniceng220er4tab3"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab3/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab3/?report=previmg" alt="Table 3. Summary of studies included in the evidence review." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab3"><a href="/books/NBK585274/table/niceng220er4.tab3/?report=objectonly" target="object" rid-ob="figobniceng220er4tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div></div><div id="niceng220er4.s1.1.5.3"><h5>1.1.5.3. Amantadine compared to placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab4"><a href="/books/NBK585274/table/niceng220er4.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab4" rid-ob="figobniceng220er4tab4"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab4/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab4/?report=previmg" alt="Table 4. Summary of studies included in the evidence review." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab4"><a href="/books/NBK585274/table/niceng220er4.tab4/?report=objectonly" target="object" rid-ob="figobniceng220er4tab4">Table 4</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div></div><div id="niceng220er4.s1.1.5.4"><h5>1.1.5.4. SSRIs compared to placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab5"><a href="/books/NBK585274/table/niceng220er4.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab5" rid-ob="figobniceng220er4tab5"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab5/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab5/?report=previmg" alt="Table 5. Summary of studies included in the evidence review." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab5"><a href="/books/NBK585274/table/niceng220er4.tab5/?report=objectonly" target="object" rid-ob="figobniceng220er4tab5">Table 5</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div></div><div id="niceng220er4.s1.1.5.5"><h5>1.1.5.5. Aspirin compared to placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab6"><a href="/books/NBK585274/table/niceng220er4.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab6" rid-ob="figobniceng220er4tab6"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab6/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab6/?report=previmg" alt="Table 6. Summary of studies included in the evidence review." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab6"><a href="/books/NBK585274/table/niceng220er4.tab6/?report=objectonly" target="object" rid-ob="figobniceng220er4tab6">Table 6</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div></div><div id="niceng220er4.s1.1.5.6"><h5>1.1.5.6. Modafinil compared to placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab7"><a href="/books/NBK585274/table/niceng220er4.tab7/?report=objectonly" target="object" title="Table 7" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab7" rid-ob="figobniceng220er4tab7"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab7/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab7/?report=previmg" alt="Table 7. Summary of studies included in the evidence review." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab7"><a href="/books/NBK585274/table/niceng220er4.tab7/?report=objectonly" target="object" rid-ob="figobniceng220er4tab7">Table 7</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div></div><div id="niceng220er4.s1.1.5.7"><h5>1.1.5.7. Combination of pharmacological therapies (amantadine and aspirin) compared to amantadine</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab8"><a href="/books/NBK585274/table/niceng220er4.tab8/?report=objectonly" target="object" title="Table 8" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab8" rid-ob="figobniceng220er4tab8"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab8/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab8/?report=previmg" alt="Table 8. Summary of studies included in the evidence review." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab8"><a href="/books/NBK585274/table/niceng220er4.tab8/?report=objectonly" target="object" rid-ob="figobniceng220er4tab8">Table 8</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div><p>See <a href="#niceng220er4.appd">Appendix D</a> for full evidence tables.</p></div></div><div id="niceng220er4.s1.1.6"><h4>1.1.6. Summary of the effectiveness evidence</h4><div id="niceng220er4.s1.1.6.1"><h5>1.1.6.1. Amantadine compared to aspirin</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab9"><a href="/books/NBK585274/table/niceng220er4.tab9/?report=objectonly" target="object" title="Table 9" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab9" rid-ob="figobniceng220er4tab9"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab9/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab9/?report=previmg" alt="Table 9. Clinical evidence summary: amantadine compared to aspirin." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab9"><a href="/books/NBK585274/table/niceng220er4.tab9/?report=objectonly" target="object" rid-ob="figobniceng220er4tab9">Table 9</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: amantadine compared to aspirin. </p></div></div></div><div id="niceng220er4.s1.1.6.2"><h5>1.1.6.2. Amantadine compared to modafinil</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab10"><a href="/books/NBK585274/table/niceng220er4.tab10/?report=objectonly" target="object" title="Table 10" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab10" rid-ob="figobniceng220er4tab10"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab10/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab10/?report=previmg" alt="Table 10. Clinical evidence summary: amantadine compared to modafinil." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab10"><a href="/books/NBK585274/table/niceng220er4.tab10/?report=objectonly" target="object" rid-ob="figobniceng220er4tab10">Table 10</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: amantadine compared to modafinil. </p></div></div></div><div id="niceng220er4.s1.1.6.3"><h5>1.1.6.3. Amantadine compared to placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab11"><a href="/books/NBK585274/table/niceng220er4.tab11/?report=objectonly" target="object" title="Table 11" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab11" rid-ob="figobniceng220er4tab11"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab11/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab11/?report=previmg" alt="Table 11. Clinical evidence summary: amantadine compared to placebo." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab11"><a href="/books/NBK585274/table/niceng220er4.tab11/?report=objectonly" target="object" rid-ob="figobniceng220er4tab11">Table 11</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: amantadine compared to placebo. </p></div></div></div><div id="niceng220er4.s1.1.6.4"><h5>1.1.6.4. SSRIs compared to placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab12"><a href="/books/NBK585274/table/niceng220er4.tab12/?report=objectonly" target="object" title="Table 12" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab12" rid-ob="figobniceng220er4tab12"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab12/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab12/?report=previmg" alt="Table 12. Clinical evidence summary: SSRIs compared to placebo." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab12"><a href="/books/NBK585274/table/niceng220er4.tab12/?report=objectonly" target="object" rid-ob="figobniceng220er4tab12">Table 12</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: SSRIs compared to placebo. </p></div></div></div><div id="niceng220er4.s1.1.6.5"><h5>1.1.6.5. Aspirin compared to placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab13"><a href="/books/NBK585274/table/niceng220er4.tab13/?report=objectonly" target="object" title="Table 13" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab13" rid-ob="figobniceng220er4tab13"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab13/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab13/?report=previmg" alt="Table 13. Clinical evidence summary: aspirin compared to placebo." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab13"><a href="/books/NBK585274/table/niceng220er4.tab13/?report=objectonly" target="object" rid-ob="figobniceng220er4tab13">Table 13</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: aspirin compared to placebo. </p></div></div></div><div id="niceng220er4.s1.1.6.6"><h5>1.1.6.6. Modafinil compared to placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab14"><a href="/books/NBK585274/table/niceng220er4.tab14/?report=objectonly" target="object" title="Table 14" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab14" rid-ob="figobniceng220er4tab14"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab14/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab14/?report=previmg" alt="Table 14. Clinical evidence summary: modafinil compared to placebo." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab14"><a href="/books/NBK585274/table/niceng220er4.tab14/?report=objectonly" target="object" rid-ob="figobniceng220er4tab14">Table 14</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: modafinil compared to placebo. </p></div></div></div><div id="niceng220er4.s1.1.6.7"><h5>1.1.6.7. Combination of pharmacological therapies (amantadine and aspirin) compared to amantadine</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab15"><a href="/books/NBK585274/table/niceng220er4.tab15/?report=objectonly" target="object" title="Table 15" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab15" rid-ob="figobniceng220er4tab15"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab15/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab15/?report=previmg" alt="Table 15. Clinical evidence summary: combination of pharmacological therapies (amantadine and aspirin) compared to amantadine." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab15"><a href="/books/NBK585274/table/niceng220er4.tab15/?report=objectonly" target="object" rid-ob="figobniceng220er4tab15">Table 15</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: combination of pharmacological therapies (amantadine and aspirin) compared to amantadine. </p></div></div><p>See <a href="#niceng220er4.appf">Appendix F</a> for full GRADE tables.</p></div></div><div id="niceng220er4.s1.1.7"><h4>1.1.7. Economic evidence</h4><div id="niceng220er4.s1.1.7.1"><h5>1.1.7.1. Included studies</h5><p>No health economic studies were included.</p></div><div id="niceng220er4.s1.1.7.2"><h5>1.1.7.2. Excluded studies</h5><p>No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.</p><p>See also the health economic study selection flow chart in <a href="#niceng220er4.appg">Appendix G</a>.</p></div></div><div id="niceng220er4.s1.1.8"><h4>1.1.8. Summary of included economic evidence</h4><p>None</p></div><div id="niceng220er4.s1.1.9"><h4>1.1.9. Economic model</h4><p>This area was not prioritised for new cost-effectiveness analysis.</p></div><div id="niceng220er4.s1.1.10"><h4>1.1.10. Unit costs</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4tab16"><a href="/books/NBK585274/table/niceng220er4.tab16/?report=objectonly" target="object" title="Table 16" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4tab16" rid-ob="figobniceng220er4tab16"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.tab16/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.tab16/?report=previmg" alt="Table 16. Unit cost of drugs for the management of fatigue." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.tab16"><a href="/books/NBK585274/table/niceng220er4.tab16/?report=objectonly" target="object" rid-ob="figobniceng220er4tab16">Table 16</a></h4><p class="float-caption no_bottom_margin">Unit cost of drugs for the management of fatigue. </p></div></div><p>For modafinil, the BNF states that an electrocardiogram (ECG) is required before initiation. The unit cost of an ECG is £61.80 (NHS reference cost 2019/2020,<a class="bibr" href="#niceng220er4.s1.1.ref18" rid="niceng220er4.s1.1.ref18"><sup>18</sup></a> currency code: EY51Z).</p></div><div id="niceng220er4.s1.1.11"><h4>1.1.11. Evidence statements</h4><div id="niceng220er4.s1.1.11.1"><h5>Effectiveness</h5><p>See summary of evidence in <u>Tables 14–20</u>.</p></div><div id="niceng220er4.s1.1.11.2"><h5>Economic</h5><ul><li class="half_rhythm"><div>No relevant economic evaluations were identified.</div></li></ul></div></div><div id="niceng220er4.s1.1.12"><h4>1.1.12. The committee’s discussion and interpretation of the evidence</h4><div id="niceng220er4.s1.1.12.1"><h5>1.1.12.1. The outcomes that matter most</h5><p>The committee agreed that all outcomes included in the protocol were of critical importance for decision-making. The outcomes included patient-reported measures to assess MS fatigue, Visual Analogue Scale (VAS), adverse effects of treatment, Health-related Quality of Life (HRQoL), impact on patients and carers, cognitive functions, and psychological symptoms assessed by validated and disease-specific scales or questionnaires.</p><p>No evidence from randomised controlled trials was identified for VAS or impact on patients/carers.</p></div><div id="niceng220er4.s1.1.12.2"><h5>1.1.12.2. The quality of the evidence</h5><p>Seventeen randomised controlled trials including all 8 studies from the previous guideline were included in the review. Twelve of these were parallel trials and 5 were crossover trials. Evidence was available for the following comparisons:
|
|
<ul><li class="half_rhythm"><div>Amantadine compared to aspirin</div></li><li class="half_rhythm"><div>Amantadine compared to modafinil</div></li><li class="half_rhythm"><div>Amantadine compared to placebo</div></li><li class="half_rhythm"><div>SSRIs compared to placebo (analysed as a class, the formulations included are):
|
|
<ul class="circle"><li class="half_rhythm"><div>Fluoxetine compared to placebo</div></li><li class="half_rhythm"><div>Paroxetine compares to placebo</div></li></ul></div></li><li class="half_rhythm"><div>Aspirin compared to placebo</div></li><li class="half_rhythm"><div>Modafinil compared to placebo</div></li><li class="half_rhythm"><div>Combination of pharmacological therapies (amantadine and aspirin) compared to amantadine</div></li></ul></p><p>There was no evidence available comparing any intervention with usual care or clinical effectiveness beyond 6 months. There was limited evidence comparing active treatments to each other and comparing combinations of treatments to other treatments and placebo. There was also very limited evidence on adverse events.</p><p>In general, the quality of the evidence as assessed by GRADE was very low. Downgrading was most often due to indirectness for follow up as the majority of studies had a follow up time of less than 3 months and did not fulfil a period of 3–6 months as stated in the protocol. In addition, risk of bias due to selection or attrition bias was another reason for downgrading the evidence. In some scenarios, baseline values were different which could have influenced the effect on the meta-analysis. This information was presented to the committee to inform their confidence in the relative treatment effect. Imprecision in the outcomes was common. There was inconsistency in the evidence for Modified Fatigue Impact Scale in studies comparing amantadine to modafinil and for studies comparing amantadine to placebo with statistical heterogeneity being present. In these scenarios, only two or three studies were included in the meta-analysis and therefore there was an insufficient number of studies to produce substantial subgroups for a subgroup analysis. Therefore, the outcomes were analysed using random effects and downgraded for inconsistency.</p><div id="niceng220er4.s1.1.12.2.1"><h5>1.1.12.2.1. Amantadine compared to aspirin</h5><p>One outcome was reported (patient-reported outcome measures to assess MS fatigue at 3–6 months) including one small study (N=52). This outcome was rated as very low quality due to risk of bias, outcome indirectness and imprecision.</p></div><div id="niceng220er4.s1.1.12.2.2"><h5>1.1.12.2.2. Amantadine compared to modafinil</h5><p>Six outcomes were reported, including evidence from two studies. The outcomes were all of very low quality (apart from Epworth Sleepiness Scale at 3–6 months which was of low quality) and were commonly downgraded for risk of bias, outcome indirectness and imprecision. The patient-reported outcome measures to assess MS fatigue outcome was downgraded for inconsistency due to heterogeneity in the outcome.</p></div><div id="niceng220er4.s1.1.12.2.3"><h5>1.1.12.2.3. Amantadine compared to placebo</h5><p>Twenty-six outcomes were reported, including evidence from eight studies. The outcomes were all of very low quality (apart from Epworth Sleepiness Scale at 3–6 months which was of low quality) and were commonly downgraded for risk of bias, outcome indirectness and imprecision. The patient-reported outcome measures to assess MS fatigue outcome was downgraded for inconsistency due to heterogeneity in the outcome. The adverse events leading to withdrawal and cardiac events/arrhythmias outcomes were also downgraded for inconsistency due to zero events in some, but not all, studies included in the meta-analysis.</p></div><div id="niceng220er4.s1.1.12.2.4"><h5>1.1.12.2.4. SSRIs compared to placebo</h5><p>Sixteen outcomes were reported, including evidence from 3 studies. The outcomes ranged from high to very low quality, with the majority being of moderate-low quality. Outcomes were commonly downgraded for risk of bias, population or outcome indirectness (in this case, population indirectness is due to the inclusion of participants who have major depressive disorder as well as multiple sclerosis, and outcome indirectness being due to the outcome being at a later time period than 1 year).</p></div><div id="niceng220er4.s1.1.12.2.5"><h5>1.1.12.2.5. Aspirin compared to placebo</h5><p>One outcome was reported (withdrawal due to adverse events at 3–6 months) including one study (N=120). This outcome was rated as very low quality due to risk of bias, outcome indirectness and imprecision.</p></div><div id="niceng220er4.s1.1.12.2.6"><h5>1.1.12.2.6. Modafinil compared to placebo</h5><p>Twenty outcomes were reported, including evidence from five studies. The outcomes ranged from moderate to very low quality, with the majority of outcomes being of very low quality. Outcomes were commonly downgraded for risk of bias, outcome indirectness and imprecision.</p></div><div id="niceng220er4.s1.1.12.2.7"><h5>1.1.12.2.7. Combination of pharmacological therapies (amantadine and aspirin) compared to amantadine</h5><p>One outcome was reported (patient-reported outcome measures to assess MS fatigue at 3–6 months) including one small study (N=45). This was of moderate quality, being downgraded for outcome indirectness.</p></div></div><div id="niceng220er4.s1.1.12.3"><h5>1.1.12.3. Benefits and harms</h5><div id="niceng220er4.s1.1.12.3.1"><h5>1.1.12.3.1. Amantadine</h5><p>The effects of amantadine were investigated in ten studies and was compared to: aspirin, modafinil, combination of pharmacological therapies (amantadine and aspirin) and placebo. When compared to placebo at 3–6 months the evidence was mixed. Five outcomes (including evidence from three studies) reported a clinically important benefit for patient reported outcome measures to assess MS fatigue. There was a further patient-reported outcome measure assessing MS fatigue where the overall result of three pooled studies was ‘no clinically important difference’ between the two groups, but there was heterogeneity with one study suggesting better outcome with amantadine, one suggesting very little difference and the other suggesting worse outcome in the amantadine group. A clinically important benefit was also seen for the mental component of the SF-36 (health-related quality of life). However, the evidence for both outcomes was unclear as for patient reported outcome measures to assess MS fatigue three outcomes (including evidence from one study) showed no clinically important difference, and the physical component of SF-36 showed a clinically important harm. No clinically important difference was seen in withdrawal due to adverse events, cardiac events/arrhythmias, psychological symptoms and Epworth sleepiness scale. The evidence was unclear for cognitive functions, where one outcome showed a clinically important harm but 9 showed no clinically important difference. Disruption of sleep was observed to cause a clinically important harm (in two studies); disruption of sleep was noted to be due to insomnia in studies. Evidence was not available at the more than 6 months to 1 year time-point.</p><p>When compared to other interventions at 3–6 months, there was limited evidence. Amantadine appeared to be superior to modafinil in patient reported outcome measures to assess MS fatigue in one outcome populated by two studies. Otherwise, the same effects seen when compared to placebo were apparent for withdrawal due to adverse events, cardiac events/arrhythmias, health-related quality of life and the Epworth sleepiness scale. When compared to aspirin there was no clinically important difference between the two in patient reported outcome measures to assess MS fatigue. When compared to a combination of amantadine and aspirin, amantadine alone was inferior to the combination in patient reported outcome measures to assess MS fatigue, based on evidence from one study including 45 participants. Evidence was not available at the more than 6 months to 1 year time-point.</p><p>The committee discussed the heterogeneity in the patient-reported outcome measures to assess MS fatigue outcomes when compared to placebo. They noted that the Nourbakhsh 2021 study, a more recent study with a larger number of participants, showed no clinically important difference when compared to the other studies that showed clinically important benefits. They noted the limitations in this interpretation (as the Nourbakhsh study was a crossover trial with four study arms with a short treatment period for each intervention of 6 weeks). An additional, parallel trial (Rocca 2021) that reported the outcome at only 4 weeks suggested worse outcome with amantadine compared to the placebo group difference. This study consisted of only 15 participants in each arm. They concluded that while overall the evidence showed a clinically important benefit of amantadine, the quality of the evidence was very low and so they could not be confident in the result.</p><p>The committee discussed the clinically important harm in disruption of sleep with amantadine compared to placebo. Sleep disturbance is a common side effect of amantadine. In the included studies, amantadine was taken twice daily. Clinical experience stated that amantadine can cause sleep disturbance if taken before sleeping, as by treating fatigue it will cause disruption to sleep. The studies did not state when amantadine was taken. The committee noted that amantadine should be taken earlier in the day to minimise the possibility of sleep disturbance.</p><p>The committee noted their experiences with amantadine for fatigue. Currently amantadine is used as an initial treatment for fatigue. Lay member and clinician experience stated that amantadine can be an effective treatment for some people, but not for everyone. Currently it is unknown as to whether there are specific groups of people where this treatment would be more effective.</p><p>Based on this evidence the committee concluded that there appear to be benefits from amantadine with harms that likely could be minimised through giving people clear instructions on when to take amantadine. However, they noted the very low quality of the evidence.</p></div><div id="niceng220er4.s1.1.12.3.2"><h5>1.1.12.3.2. SSRIs</h5><p>The effects of SSRIs were investigated in three studies and was compared to placebo only. At 3–6 months the evidence was limited (being based on one study with 42 participants). This showed clinically important benefits in patient reported outcome measures to assess MS fatigue, the mental component of SF-36 (health-related quality of life), cognitive functions and psychological symptoms. There was no clinically important difference in the physical component of SF-36. Evidence from 2 studies was available at the more than 6 months to 1 year time-point. However, this evidence showed no clinically important differences in patient reported outcome measures to assess MS fatigue (based on high quality evidence), withdrawal due to adverse events, disruption of sleep, cardiac events/arrhythmias, health-related quality of life, cognitive functions and psychological symptoms.</p><p>The committee noted that benefits were seen for SSRIs at 3–6 months. However, the quality of the evidence was very low and based on one small study, which meant they were less confident in the result. Contrarily, at the more than 6 months to 1 year time-point there were no clinically important differences seen based on 2 larger studies with evidence that varied between high and very low quality. The committee agreed that there are potential benefits from using SSRIs for fatigue with no harms being found in this review.</p></div><div id="niceng220er4.s1.1.12.3.3"><h5>1.1.12.3.3. Aspirin</h5><p>The evidence on the effects of aspirin was very limited. Aspirin was compared to amantadine and placebo. When compared to placebo the only outcome reported that could be extracted as per the protocol was withdrawal due to adverse events, which showed no clinically important difference based on one study. When compared to amantadine, aspirin showed no clinically important difference in patient-reported outcome measures to assess MS fatigue. These outcomes were all at 3–6 months, with no evidence being available at the more than 6 months to 1 year time-point.</p><p>The committee noted there was an absence of evidence for this intervention. Experiences of the committee members noted that aspirin may be given by some people to treat inflammatory pain before exercise rather than to treat fatigue itself. In doing this, and reducing pain, it may help people to exercise more before feeling fatigued. As there was no evidence to show clinical benefit, the committee decided to not make a recommendation on aspirin. Instead, they made a research recommendation in order to investigate this further in the future.</p></div><div id="niceng220er4.s1.1.12.3.4"><h5>1.1.12.3.4. Modafinil</h5><p>The effects of modafinil were investigated in five studies and was compared to amantadine and placebo. When compared to placebo at 3–6 months, there was an unclear effect on health-related quality of life, with a clinically important benefit in four outcomes (based on one small study with 36 participants) while there was no clinically important difference in five outcomes (based on three studies). For all other outcomes there was no clinically important difference, including: patient reported outcome measures to assess MS fatigue, withdrawal due to adverse events, disruption of sleep, cardiac events/arrhythmias, cognitive function, psychological symptoms and Epworth sleepiness scale. There was no evidence available at the more than 6 months to 1 year time-point.</p><p>When compared to amantadine at 3–6 months, there was limited evidence. Modafinil appeared to be inferior to amantadine in patient reported outcome measures to assess MS fatigue in one outcome populated by two studies. There was an unclear effect on health-related quality of life (based on one small study with 30 participants) where modafinil appeared to be superior in the physical component of SF-36 (health-related quality of life) and inferior in the mental component of SF-36. Otherwise, the same effects seen when compared to placebo were apparent for withdrawal due to adverse events, cardiac events/arrhythmias and the Epworth sleepiness scale. There was no evidence available at the more than 6 months to 1 year time-point.</p><p>The committee acknowledged that there was limited evidence showing a benefit for health-related quality of life only. However, the quality for all outcomes was between moderate and very low, therefore they were ultimately not confident in the results. The committee noted that although modafinil is commonly prescribed in secondary care, the person should be offered modafinil as a first line option. In the committee’s experience, modafinil could be particularly effective for people with excessive sleepiness. This subgroup was not investigated in this review.</p><p>Based on the absence of harms and potential benefits, modafinil was included in the list of drugs to be considered for people with MS wishing to try a medicine for fatigue. The committee noted that the evidence was of low quality and that, based on clinical experience and consensus within the committee, there may be specific groups of people that would benefit more from modafinil (for example, people with fatigue and excessive sleepiness). Based on this, they made a research recommendation to gain more information about groups where this treatment could be more effective.</p><p>Amantadine, SSRIs and modafinil were all recommended as first line options for the treatment of fatigue. Due to the lack of evidence the committee were unable to suggest a preference for what medication should be tried first and emphasised that individual patient factors need to be taken into consideration when discussing options. Response should be monitored and reviewed so that people do not remain on ineffective treatment.</p></div><div id="niceng220er4.s1.1.12.3.5"><h5>1.1.12.3.5. Combination of pharmacological therapies (amantadine and aspirin)</h5><p>There was very limited evidence on the efficacy of combination of pharmacological therapies. One study reported comparing amantadine and aspirin to amantadine alone at 3–6 months. In this there was a clinically important benefit of the combination of pharmacological therapies in patient reported outcome measures to assess MS fatigue (based on one small study including 45 participants). There was no evidence available at the more than 6 months to 1 year time-point.</p><p>The committee noted the limited evidence for this comparison and for aspirin alone compared to placebo. Based on this they decided to not make a recommendation discussing combinations of pharmacological therapies. Instead, they made a research recommendation in order to investigate this further in the future.</p></div></div><div id="niceng220er4.s1.1.12.4"><h5>1.1.12.4. Cost effectiveness and resource use</h5><p>No relevant health economic analyses were identified for this review; therefore, unit costs were presented to aid committee consideration of cost-effectiveness. The annual unit cost of amantadine ranged between approximately £350 and £701, which was significantly more expensive than the other drugs in the clinical studies. The estimated cost of modafinil was between £78 and £157 per year, in addition there is a one of cost of an ECG prior to drug initiation (£62). Aspirin was less costly at £18 per year while the SSRIs fluoxetine and paroxetine were costed at £14-£22 and £56-£41 per year, respectively.</p><div id="niceng220er4.s1.1.12.4.1"><h5>Amantadine</h5><p>The clinical evidence summarised in the section above reported a clinically important benefit for patient reported outcome measures to assess MS fatigue for amantadine vs placebo. A clinically important benefit was also seen for the mental component of the SF-36 (health-related quality of life). A clinically important harm was reported in disruption of sleep with amantadine compared to placebo. The committee noted that this likely could be minimised through giving people clear instructions on when to take amantadine. There was limited evidence comparing amantadine to other comparators. The previous MS guideline made an ‘offer’ recommendation for the use of amantadine to treat fatigue in people with MS, however, it was noted that the cost of amantadine had increased since the development of the last guideline. Experiences of committee members noted that amantadine is usually the conventional treatment for MS-related fatigue and can be an effective treatment for some people, but not for everyone. At the current cost, prescribing amantadine is likely to have a substantial resource impact, as annual costs start at £350, and any treatment costing over £100 affecting 10% of the MS population would be considered a substantial resource impact. Given the lack of published health economic evidence, the increased cost and the very low quality of clinical evidence, a ‘consider’ recommendation was made for amantadine.</p></div><div id="niceng220er4.s1.1.12.4.2"><h5>Modafinil</h5><p>The committee acknowledged that there was limited or unclear evidence showing the benefit of modafinil in terms of health-related quality of life when compared to placebo or amantadine. Some committee members suggested there could be potential improvements to quality of life in terms of employment, as this would improve productivity for people with MS, however, there was no clinical evidence for this and health economic evidence for NICE guidelines does not consider the impact of employment in terms of GDP or productivity of the workforce. The committee acknowledged that there would be a resource impact for recommending modafinil, however, they highlighted that a lower dose (100mg) than what was shown in the studies is commonly prescribed. If 10% of people with MS were treated with the lower dose (~£40 per year) then this would be below the threshold of what is considered a substantial resource impact. Given the limited clinical evidence and lack of cost-effective evidence the committee agreed on a ‘consider’ recommendation for modafinil.</p></div><div id="niceng220er4.s1.1.12.4.3"><h5>SSRIs</h5><p>Clinically important benefits were reported for patient reported outcome measures to assess MS fatigue, the mental component of SF-36 (health-related quality of life), cognitive functions and psychological symptoms. Both SSRIs were also less costly than amantadine. No clinically important harms were found in the clinical review, however, the quality of evidence for benefits seen for SSRIs at 3–6 months was very low and based on one study. Given the potential benefits from SSRIs for fatigue and lack of serious adverse events based on the clinical review, committee agreed on a ‘consider’ recommendation for SSRIs.</p></div><div id="niceng220er4.s1.1.12.4.4"><h5>Aspirin</h5><p>Experiences of committee members noted that aspirin would not be given to treat fatigue specifically but rather to alleviate inflammatory pain before exercising. Alongside this, there was no evidence of clinical benefit of aspirin for treating fatigue and as such the committee agreed not to make a recommendation for the use of aspirin to manage MS-related fatigue.</p><p>In conclusion, based on the limited clinical and economic evidence, the committee agreed to make a consider recommendation for amantadine, modafinil and SSRIs. In terms of current practice, amantadine is currently the first-line pharmacological treatment and modafinil is mostly provided in secondary care settings. Given that all three drugs are considered equally, there may be a decrease in use of amantadine and increase in use of modafinil and SSRIs. Given that the unit cost of amantadine is greater than that of modafinil and SSRIs the resource impact of this recommendation is unlikely to be significant.</p></div></div><div id="niceng220er4.s1.1.12.5"><h5>1.1.12.5. Other factors the committee took into account</h5><p>The committee noted that currently modafinil is mostly prescribed by secondary care physicians, while amantadine is prescribed by a range of professionals across sectors. Through this recommendation, they believe that practice may change and so modafinil may be prescribed more by different professionals and in primary care.</p><p>The committee noted the safety concerns for modafinil, including that it should not be used during pregnancy and that precautions should be taken if prescribing it for women able to have children, in line with the 2020 MHRA safety advice on modafinil. The committee noted additional advice on monitoring, stopping treatment and cautions for use in the 2014 MHRA safety advice on modafinil and in the summary of product characteristics for modafinil and amantadine.</p></div></div><div id="niceng220er4.s1.1.13"><h4>1.1.13. Recommendations supported by this evidence review</h4><p>This evidence review supports recommendations 1.5.12 to 1.5.16 and the research recommendation on pharmacological management of fatigue.</p></div><div id="niceng220er4.s1.1.rl.r1"><h4>1.1.14. References</h4><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref1">Anonymous. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Canadian Journal of Neurological Sciences. 1987; 14(3):273–278 [<a href="https://pubmed.ncbi.nlm.nih.gov/2889518" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2889518</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref2">Ashtari
|
|
F, Fatehi
|
|
F, Shaygannejad
|
|
V, Chitsaz
|
|
A. Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?
|
|
Polish Journal of Neurology and Neurosurgery. 2009; 43(5):428–432 [<a href="https://pubmed.ncbi.nlm.nih.gov/20054744" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20054744</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref3">BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National Formulary. 2021. Available from: <a href="https://bnf.nice.org.uk/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://bnf<wbr style="display:inline-block"></wbr>​.nice.org.uk/</a> Last accessed: 06 October 2021.</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref4">Cambron
|
|
M, Mostert
|
|
J, D’Hooghe
|
|
M, Nagels
|
|
G, Willekens
|
|
B, Debruyne
|
|
J
|
|
et al
|
|
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial. Multiple Sclerosis. 2019; 25(13):1728–1735 [<a href="https://pubmed.ncbi.nlm.nih.gov/31218911" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31218911</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref5">Cambron
|
|
M, Mostert
|
|
J, Parra
|
|
J, D’Hooghe
|
|
M, Nagels
|
|
G, Willekens
|
|
B
|
|
et al
|
|
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS). Multiple Sclerosis. 2016; 22(Suppl 3):832–833</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref6">Chataway
|
|
J, Chandran
|
|
S, Miller
|
|
D, Giovannoni
|
|
G, Wheeler-Kingshott
|
|
C, Pavitt
|
|
S
|
|
et al
|
|
The MS-smart trial in secondary progressive multiple sclerosis: A multi-arm, multi-centre trial of neuroprotection. Journal of Neurology, Neurosurgery and Psychiatry. 2015; 86:e4</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref7">Chataway
|
|
J, De Angelis
|
|
F, Connick
|
|
P, Parker
|
|
RA, Plantone
|
|
D, Doshi
|
|
A
|
|
et al
|
|
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. The Lancet Neurology. 2020; 19(3):214–225 [<a href="/pmc/articles/PMC7029307/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7029307</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31981516" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31981516</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref8">Cohen
|
|
RA, Fisher
|
|
M. Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology. 1989; 46(6):676–680 [<a href="https://pubmed.ncbi.nlm.nih.gov/2730380" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2730380</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref9">Ehde
|
|
DM, Kraft
|
|
GH, Chwastiak
|
|
L, Sullivan
|
|
MD, Gibbons
|
|
LE, Bombardier
|
|
CH
|
|
et al
|
|
Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. General Hospital Psychiatry. 2008; 30(1):40–48 [<a href="https://pubmed.ncbi.nlm.nih.gov/18164939" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18164939</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref10">Ford-Johnson
|
|
L, DeLuca
|
|
J, Zhang
|
|
J, Elovic
|
|
E, Lengenfelder
|
|
J, Chiaravalloti
|
|
ND. Cognitive effects of modafinil in patients with multiple sclerosis: A clinical trial. Rehabilitation Psychology. 2016; 61(1):82–91 [<a href="https://pubmed.ncbi.nlm.nih.gov/26654280" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26654280</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref11">Geisler
|
|
MW, Sliwinski
|
|
M, Coyle
|
|
PK, Masur
|
|
DM, Doscher
|
|
C, Krupp
|
|
LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology. 1996; 53(2):185–188 [<a href="https://pubmed.ncbi.nlm.nih.gov/8639070" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8639070</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref12">Hamzei-Moghaddam A SBIFAM. Therapeutic effect of co-administration of amantadine and aspirin on fatigue in patients with multiple sclerosis: A randomized placebo-controlled double-blind study. Iranian Journal of Pharmacology and Therapeutics. 2011; 10(2):71–75</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref13">Krupp
|
|
LB, Coyle
|
|
PK, Doscher
|
|
C, Miller
|
|
A, Cross
|
|
AH, Jandorf
|
|
L
|
|
et al
|
|
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995; 45(11):1956–1961 [<a href="https://pubmed.ncbi.nlm.nih.gov/7501140" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7501140</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref14">Ledinek
|
|
AH, Sajko
|
|
MC, Rot
|
|
U. Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis - result of a pilot randomized, blind study. Clinical Neurology and Neurosurgery. 2013; 115(Supp 1):S86–89 [<a href="https://pubmed.ncbi.nlm.nih.gov/24321164" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24321164</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref15">Möller
|
|
F, Poettgen
|
|
J, Broemel
|
|
F, Neuhaus
|
|
A, Daumer
|
|
M, Heesen
|
|
C. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Multiple Sclerosis. 2011; 17(8):1002–1009 [<a href="https://pubmed.ncbi.nlm.nih.gov/21561959" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21561959</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref16">Murray
|
|
TJ. Amantadine therapy for fatigue in multiple sclerosis. Canadian Journal of Neurological Sciences. 1985; 12(3):251–254 [<a href="https://pubmed.ncbi.nlm.nih.gov/3902184" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3902184</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref17">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated 2020]. London. National Institute for Health and Care Excellence, 2014. Available from: <a href="http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nice.org.uk<wbr style="display:inline-block"></wbr>​/article/PMG20/chapter<wbr style="display:inline-block"></wbr>​/1%20Introduction%20and%20overview</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/26677490" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26677490</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref18">NHS England and NHS Improvement. 2019/20 National Cost Collection Data Publication. 2021. Available from: <a href="https://www.england.nhs.uk/publication/2019-20-national-cost-collection-data-publication/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.england.nhs<wbr style="display:inline-block"></wbr>​.uk/publication/2019-20-national-cost-collection-data-publication/</a> Last accessed: 04 October 2021.</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref19">Nourbakhsh
|
|
B, Revirajan
|
|
N, Morris
|
|
B, Cordano
|
|
C, Creasman
|
|
J, Manguinao
|
|
M
|
|
et al
|
|
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. The Lancet Neurology. 2021; 20(1):38–48 [<a href="/pmc/articles/PMC7772747/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7772747</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33242419" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33242419</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>20.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref20">Nourbakhsh
|
|
B, Revirajan
|
|
N, Waubant
|
|
E. Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. Contemporary Clinical Trials. 2018; 64:67–76 [<a href="https://pubmed.ncbi.nlm.nih.gov/29113955" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29113955</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>21.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref21">Payne
|
|
C, Wiffen
|
|
PJ, Martin
|
|
S. Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database of Systematic Reviews
|
|
2017, Issue 4. Art. No.: CD008427. DOI: 10.1002/14651858.cd008427.pub3. [<a href="https://pubmed.ncbi.nlm.nih.gov/22258985" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22258985</span></a>] [<a href="http://dx.crossref.org/10.1002/14651858.cd008427.pub3" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></dd></dl><dl class="bkr_refwrap"><dt>22.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref22">Rocca
|
|
MA, Valsasina
|
|
P, Colombo
|
|
B, Martinelli
|
|
V, Filippi
|
|
M. Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. European Journal of Neurology. 2021; 28(7):2249–2258 [<a href="https://pubmed.ncbi.nlm.nih.gov/33852752" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33852752</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>23.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref23">Rosenberg
|
|
GA, Appenzeller
|
|
O. Amantadine, fatigue, and multiple sclerosis. Archives of Neurology. 1988; 45(10):1104–1106 [<a href="https://pubmed.ncbi.nlm.nih.gov/2972270" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2972270</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>24.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref24">Sadeghi-Naini
|
|
M, Ghazi-zadeh Esslami
|
|
G, Fayyazi
|
|
S, Nabavi
|
|
SM, Morsali
|
|
D, Ghaffarpour
|
|
M. Low dose aspirin for MS-related fatigue: Results of a pilot, double-blind, randomized trial. Neurology Psychiatry and Brain Research. 2017; 25:24–30</div></dd></dl><dl class="bkr_refwrap"><dt>25.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref25">Shaygannejad
|
|
V, Janghorbani
|
|
M, Ashtari
|
|
F, Zakeri
|
|
H. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research. 2012; 34(9):854–858 [<a href="https://pubmed.ncbi.nlm.nih.gov/22979982" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22979982</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>26.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref26">Stankoff
|
|
B, Waubant
|
|
E, Confavreux
|
|
C, Edan
|
|
G, Debouverie
|
|
M, Rumbach
|
|
L
|
|
et al
|
|
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005; 64(7):1139–1143 [<a href="https://pubmed.ncbi.nlm.nih.gov/15824337" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15824337</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>27.</dt><dd><div class="bk_ref" id="niceng220er4.s1.1.ref27">Wu
|
|
S, Kutlubaev
|
|
MA, Chun
|
|
HYY, Cowey
|
|
E, Pollock
|
|
A, Macleod
|
|
MR
|
|
et al
|
|
Interventions for post-stroke fatigue. Cochrane Database of Systematic Reviews
|
|
2015, Issue 7. Art. No.: CD007030. DOI: 10.1002/14651858.cd007030.pub3. [<a href="/pmc/articles/PMC7387276/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7387276</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26133313" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26133313</span></a>] [<a href="http://dx.crossref.org/10.1002/14651858.cd007030.pub3" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></dd></dl></dl></div></div></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng220er4.appa"><h3>Appendix A. Review protocols</h3><p id="niceng220er4.appa.et1"><a href="/books/NBK585274/bin/niceng220er4-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Review protocol for pharmacological management of fatigue</a><span class="small"> (PDF, 242K)</span></p><p id="niceng220er4.appa.et2"><a href="/books/NBK585274/bin/niceng220er4-appa-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Health economic review protocol</a><span class="small"> (PDF, 157K)</span></p></div><div id="niceng220er4.appb"><h3>Appendix B. Literature search strategies</h3><p>This literature search strategy was used for the following review:
|
|
<ul><li class="half_rhythm"><div>The clinical and cost effectiveness of pharmacological interventions for fatigue for adults with MS, including people receiving palliative care.</div></li></ul></p><p>The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.<a class="bibr" href="#niceng220er4.s1.1.ref17" rid="niceng220er4.s1.1.ref17"><sup>17</sup></a></p><p>For more information, please see the Methodology review published as part of the accompanying documents for this guideline.</p><p id="niceng220er4.appb.et1"><a href="/books/NBK585274/bin/niceng220er4-appb-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">B.1. Clinical search literature search strategy</a><span class="small"> (PDF, 162K)</span></p><p id="niceng220er4.appb.et2"><a href="/books/NBK585274/bin/niceng220er4-appb-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">B.2. Health Economics literature search strategy</a><span class="small"> (PDF, 166K)</span></p></div><div id="niceng220er4.appc"><h3>Appendix C. Effectiveness evidence study selection</h3><p id="niceng220er4.appc.et1"><a href="/books/NBK585274/bin/niceng220er4-appc-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 1. Flow chart of clinical study selection for the review of the pharmacological management of fatigue in people with multiple sclerosis</a><span class="small"> (PDF, 100K)</span></p></div><div id="niceng220er4.appd"><h3>Appendix D. Effectiveness evidence</h3><p id="niceng220er4.appd.et1"><a href="/books/NBK585274/bin/niceng220er4-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (1.1M)</span></p></div><div id="niceng220er4.appe"><h3>Appendix E. Forest plots</h3><p id="niceng220er4.appe.et1"><a href="/books/NBK585274/bin/niceng220er4-appe-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Amantadine compared to aspirin</a><span class="small"> (PDF, 93K)</span></p><p id="niceng220er4.appe.et2"><a href="/books/NBK585274/bin/niceng220er4-appe-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Amantadine compared to modafinil</a><span class="small"> (PDF, 101K)</span></p><p id="niceng220er4.appe.et3"><a href="/books/NBK585274/bin/niceng220er4-appe-et3.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Amantadine compared to placebo</a><span class="small"> (PDF, 181K)</span></p><p id="niceng220er4.appe.et4"><a href="/books/NBK585274/bin/niceng220er4-appe-et4.pdf" class="bk_dwnld_icn bk_dwnld_pdf">SSRIs compared to placebo</a><span class="small"> (PDF, 165K)</span></p><p id="niceng220er4.appe.et5"><a href="/books/NBK585274/bin/niceng220er4-appe-et5.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Aspirin compared to placebo</a><span class="small"> (PDF, 93K)</span></p><p id="niceng220er4.appe.et6"><a href="/books/NBK585274/bin/niceng220er4-appe-et6.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Modafinil compared to placebo</a><span class="small"> (PDF, 173K)</span></p><p id="niceng220er4.appe.et7"><a href="/books/NBK585274/bin/niceng220er4-appe-et7.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Combination of pharmacological therapies (amantadine and aspirin) compared to amantadine</a><span class="small"> (PDF, 93K)</span></p></div><div id="niceng220er4.appf"><h3>Appendix F. GRADE and/or GRADE-CERQual tables</h3><p id="niceng220er4.appf.et1"><a href="/books/NBK585274/bin/niceng220er4-appf-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Amantadine compared to aspirin</a><span class="small"> (PDF, 173K)</span></p><p id="niceng220er4.appf.et2"><a href="/books/NBK585274/bin/niceng220er4-appf-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Amantadine compared to modafinil</a><span class="small"> (PDF, 188K)</span></p><p id="niceng220er4.appf.et3"><a href="/books/NBK585274/bin/niceng220er4-appf-et3.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Amantadine compared to placebo</a><span class="small"> (PDF, 251K)</span></p><p id="niceng220er4.appf.et4"><a href="/books/NBK585274/bin/niceng220er4-appf-et4.pdf" class="bk_dwnld_icn bk_dwnld_pdf">SSRIs compared to placebo</a><span class="small"> (PDF, 209K)</span></p><p id="niceng220er4.appf.et5"><a href="/books/NBK585274/bin/niceng220er4-appf-et5.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Aspirin compared to placebo</a><span class="small"> (PDF, 172K)</span></p><p id="niceng220er4.appf.et6"><a href="/books/NBK585274/bin/niceng220er4-appf-et6.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Modafinil compared to placebo</a><span class="small"> (PDF, 220K)</span></p><p id="niceng220er4.appf.et7"><a href="/books/NBK585274/bin/niceng220er4-appf-et7.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Combination of pharmacological therapies (amantadine and aspirin) compared to amantadine</a><span class="small"> (PDF, 173K)</span></p></div><div id="niceng220er4.appg"><h3>Appendix G. Economic evidence study selection</h3><p id="niceng220er4.appg.et1"><a href="/books/NBK585274/bin/niceng220er4-appg-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 73. Flow chart of health economic study selection for the guideline</a><span class="small"> (PDF, 113K)</span></p></div><div id="niceng220er4.apph"><h3>Appendix H. Economic evidence tables</h3><p>None.</p></div><div id="niceng220er4.appi"><h3>Appendix I. Health economic model</h3><p>No original health economic modelling was undertaken as other areas of the guideline were prioritised.</p></div><div id="niceng220er4.appj"><h3>Appendix J. Excluded studies</h3><div id="niceng220er4.appj.s1"><h4>Clinical studies</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng220er4appjtab26"><a href="/books/NBK585274/table/niceng220er4.appj.tab26/?report=objectonly" target="object" title="Table 26" class="img_link icnblk_img figpopup" rid-figpopup="figniceng220er4appjtab26" rid-ob="figobniceng220er4appjtab26"><img class="small-thumb" src="/books/NBK585274/table/niceng220er4.appj.tab26/?report=thumb" src-large="/books/NBK585274/table/niceng220er4.appj.tab26/?report=previmg" alt="Table 26. Studies excluded from the clinical review." /></a><div class="icnblk_cntnt"><h4 id="niceng220er4.appj.tab26"><a href="/books/NBK585274/table/niceng220er4.appj.tab26/?report=objectonly" target="object" rid-ob="figobniceng220er4appjtab26">Table 26</a></h4><p class="float-caption no_bottom_margin">Studies excluded from the clinical review. </p></div></div></div><div id="niceng220er4.appj.s2"><h4>Health Economic studies</h4><p id="niceng220er4.appj.et1"><a href="/books/NBK585274/bin/niceng220er4-appj-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (94K)</span></p></div></div><div id="niceng220er4.appk"><h3>Appendix K. Research recommendations – full details</h3><div id="niceng220er4.appk.s1"><h4>K.1.1. Research recommendation</h4><p>For adults with MS, including people receiving palliative care, what is the clinical and cost effectiveness of pharmacological interventions for fatigue?</p></div><div id="niceng220er4.appk.s2"><h4>K.1.2. Why this is important</h4><p>Fatigue is a major problem for people with MS. Studies indicate that between 80–90% of all people with MS experience fatigue and up to 40% describe it as the most disabling symptom of the condition. Much is written regarding the effects on daily life including its impact on employment, where fatigue is one of the key factors leading to early retirement. MS fatigue is often described as primary fatigue (directly related to the condition due to causes such as nerve fibre fatigue, heat sensitive fatigue or lassitude) or secondary fatigue, where other factors may worsen the fatigue experienced, such as infection, low mood or environmental challenges. Although medications exist which may reduce fatigue, but further research is needed to identify the benefits and harms of interventions to manage these symptoms.</p></div><div id="niceng220er4.appk.s3"><h4>K.1.3. Rationale for research recommendation</h4><p id="niceng220er4.appk.et1"><a href="/books/NBK585274/bin/niceng220er4-appk-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (170K)</span></p></div><div id="niceng220er4.appk.s4"><h4>K.1.4. Modified PICO table</h4><p id="niceng220er4.appk.et2"><a href="/books/NBK585274/bin/niceng220er4-appk-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (133K)</span></p></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Evidence reviews underpinning recommendations 1.5.12 to 1.5.16 and research recommendations in the NICE guideline</p><p>National Institute for Health and Care Excellence</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2022.</div><div class="small"><span class="label">Bookshelf ID: NBK585274</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36279388" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">36279388</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng220er4tab1"><div id="niceng220er4.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng220er4.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng220er4.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Inclusion:</p>
|
|
<p>Adults (≥18 years) with MS, including people receiving palliative care, who are experiencing fatigue.</p>
|
|
<p>Exclusion:</p>
|
|
<p>Children and young people (≤18 years).</p>
|
|
</td></tr><tr><th id="hd_b_niceng220er4.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interventions</th><td headers="hd_b_niceng220er4.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Amantadine</div></li><li class="half_rhythm"><div>SSRIs</div></li><li class="half_rhythm"><div>Aspirin specifically before exercise</div></li><li class="half_rhythm"><div>Modafinil</div></li><li class="half_rhythm"><div>Combinations of the above</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_niceng220er4.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparisons</th><td headers="hd_b_niceng220er4.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interventions will be compared to each other (both within and between classes), placebo/sham, or usual care.</td></tr><tr><th id="hd_b_niceng220er4.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_niceng220er4.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All outcomes are considered equally important for decision making and therefore have all been rated as critical.
|
|
<ul><li class="half_rhythm"><div>Patient-reported outcome measures to assess MS fatigue, including MFIS Fatigue Severity Scale (FSS), National Fatigue Index (NFI), MS-specific FSS (MFSS), Modified Fatigue Impact Scale (MFIS),</div></li><li class="half_rhythm"><div>Visual Analogue Scale (VAS) for fatigue</div></li><li class="half_rhythm"><div>Adverse effects of treatment.
|
|
<ul class="circle"><li class="half_rhythm"><div>Adverse events leading to withdrawal</div></li><li class="half_rhythm"><div>Disruption of sleep</div></li><li class="half_rhythm"><div>cardiac events/arrhythmias</div></li></ul></div></li><li class="half_rhythm"><div>Health-related Quality of Life, for example EQ-5D, SF-36, Leeds MS quality of life scale, MS Impact Scale.</div></li><li class="half_rhythm"><div>Impact on patients/carers.</div></li><li class="half_rhythm"><div>Cognitive functions, such as memory and concentration</div></li><li class="half_rhythm"><div>Psychological symptoms assessed by validated and disease-specific scales, questionnaire or similar instruments.</div></li><li class="half_rhythm"><div>Epworth sleepiness scale</div></li></ul>
|
|
<b>Follow up:</b>
|
|
<ul><li class="half_rhythm"><div>3–6 months (minimum of 3 months but can include 1–3 months and downgrade)</div></li><li class="half_rhythm"><div>>6 months – 1 year (data from >1 year follow up may be included but will be downgraded)</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_niceng220er4.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng220er4.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Systematic reviews of RCTs and RCTs</p>
|
|
<p>Crossover RCTs with a washout period of at least 1 week will be included</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab2"><div id="niceng220er4.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng220er4.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng220er4.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention and comparison</th><th id="hd_h_niceng220er4.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng220er4.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Shaygannejad 2012<a class="bibr" href="#niceng220er4.s1.1.ref25" rid="niceng220er4.s1.1.ref25"><sup>25</sup></a></td><td headers="hd_h_niceng220er4.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=26)</p>
|
|
<p>Oral amantadine 100mg twice daily for 4 weeks</p>
|
|
<p>Aspirin (n=26)</p>
|
|
<p>Oral aspirin 500mg once daily for 4 weeks</p>
|
|
<p>Concomitant therapy: All people had received interferon-beta treatment for the past year.</p>
|
|
<p>Disease modifying treatment status: All participants were receiving disease modifying treatment.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 52</p>
|
|
<p>Age (mean [SD]): 35.3 (7.8) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting: 44.</p>
|
|
<p>Secondary progression: 8.</p>
|
|
<p>EDSS (mean [SD]): 1.6 (1.6)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue at 3–6 months</td><td headers="hd_h_niceng220er4.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>This study was included in the previous version of the guideline.</p>
|
|
<p>This study was a crossover trial (two-week washout).</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab3"><div id="niceng220er4.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab3_lrgtbl__"><table><thead><tr><th id="hd_h_niceng220er4.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng220er4.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention and comparison</th><th id="hd_h_niceng220er4.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng220er4.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ledinek 2013<a class="bibr" href="#niceng220er4.s1.1.ref14" rid="niceng220er4.s1.1.ref14"><sup>14</sup></a></td><td headers="hd_h_niceng220er4.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=15)</p>
|
|
<p>Amantadine 200mg orally daily for 1 month</p>
|
|
<p>Modafinil (n=15)</p>
|
|
<p>Modafinil 200mg orally daily for 1 month</p>
|
|
<p>Placebo (n=15)</p>
|
|
<p>A fourth group receiving acetyl-l-carnitine (n=15) was not extracted as it did not fulfil the inclusion criteria in the protocol.</p>
|
|
<p>Concomitant therapy: No additional information.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 60</p>
|
|
<p>Age (mean [SD]): 38.0 (6.1) years</p>
|
|
<p>Type of multiple sclerosis: Not stated/unclear.</p>
|
|
<p>EDSS: 2.7 (1.1)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Health-related Quality of Life at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was included in the previous version of the guideline.</td></tr><tr><td headers="hd_h_niceng220er4.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Nourbakhsh 2021<a class="bibr" href="#niceng220er4.s1.1.ref19" rid="niceng220er4.s1.1.ref19"><sup>19</sup></a></p>
|
|
<p>Subsidiary studies: Nourbakhsh 2018<a class="bibr" href="#niceng220er4.s1.1.ref20" rid="niceng220er4.s1.1.ref20"><sup>20</sup></a></p>
|
|
</td><td headers="hd_h_niceng220er4.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=141)</p>
|
|
<p>Oral amantadine (up to 100mg twice daily)</p>
|
|
<p>Modafinil (n=141)</p>
|
|
<p>Oral modafinil (up to 100mg twice daily)</p>
|
|
<p>Placebo (n=141)</p>
|
|
<p>A fourth group receiving methylphenidate (n=141) was reported. The results for this group was not extracted as they did not fulfil the inclusion criteria in the protocol.</p>
|
|
<p>Concomitant therapy: Not stated/unclear.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 141</p>
|
|
<p>Age (mean [SD]): 46.8 (10.7) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting MS: 106</p>
|
|
<p>Secondary progressive MS: 19</p>
|
|
<p>Primary progressive MS: 15.</p>
|
|
<p>EDSS (median [IQR]): 3 (2–4.5)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Withdrawal due to adverse events at 3–6 months</p>
|
|
<p>Cardiac events/arrhythmia at 3–6 months</p>
|
|
<p>Epworth Sleepiness scale at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a href="http://Clinicaltrials.gov" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Clinicaltrials<wbr style="display:inline-block"></wbr>​.gov</a> number: <a href="https://clinicaltrials.gov/show/NCT03185065" title="Study NCT03185065" ref="pagearea=body&targetsite=external&targetcat=link&targettype=clinical-trial">NCT03185065</a>.</p>
|
|
<p>This study was a crossover trial (two-week washout).</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab4"><div id="niceng220er4.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab4_lrgtbl__"><table><thead><tr><th id="hd_h_niceng220er4.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng220er4.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention and comparison</th><th id="hd_h_niceng220er4.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng220er4.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anonymous 1987<a class="bibr" href="#niceng220er4.s1.1.ref1" rid="niceng220er4.s1.1.ref1"><sup>1</sup></a></td><td headers="hd_h_niceng220er4.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=115)</p>
|
|
<p>100mg orally twice a day for 3 weeks (with a 2-week washout period before the study, and a 2-week washout period before crossing over to placebo treatment for 3 weeks).</p>
|
|
<p>Placebo (n=115)</p>
|
|
<p>Concomitant therapy:</p>
|
|
<p>The only concomitant medications permitted were small doses of muscle relaxants (baclofen, dantrolene) to control spasticity; anticholinergics (oxybutynin) for bladder control; and short-acting benzodiazepines at bedtime.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 115</p>
|
|
<p>Age (mean [SE]): 40.8 (1) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting: 57</p>
|
|
<p>Relapsing/progressing: 33</p>
|
|
<p>Chronic progressing: 22</p>
|
|
<p>Benign: 3</p>
|
|
<p>EDSS (mean [SE]): 4.2 (0.2)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adverse events leading to withdrawal at 3–6 months</p>
|
|
<p>Disruption of sleep at 3–6 months</p>
|
|
<p>Cardiac events/arrhythmia at 3–6 months</p>
|
|
<p>Cognitive functions at 3–6 months</p>
|
|
<p>Psychological symptoms at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Trial by the Canadian MS Research Group.</p>
|
|
<p>This study was a crossover trial (two-week washout).</p>
|
|
<p>This study was included in the previous version of the guideline.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ashtari 2009<a class="bibr" href="#niceng220er4.s1.1.ref2" rid="niceng220er4.s1.1.ref2"><sup>2</sup></a></td><td headers="hd_h_niceng220er4.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=21)</p>
|
|
<p>Oral amantadine 200mg per day for 2 months</p>
|
|
<p>Placebo (n=21)</p>
|
|
<p>Concomitant therapy: No additional information.</p>
|
|
<p>Disease modifying treatment status: All were receiving treatment with disease modifying agents (either interferon-beta, cytotoxic drugs or a combination of both).</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 41</p>
|
|
<p>Age (mean [SD]): 25.48 (5.12) years</p>
|
|
<p>Type of multiple sclerosis: Relapsing-remitting.</p>
|
|
<p>EDSS (mean [SD]): 2.56 (3.67)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Withdrawal due to adverse events at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng220er4.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cohen 1989<a class="bibr" href="#niceng220er4.s1.1.ref8" rid="niceng220er4.s1.1.ref8"><sup>8</sup></a></td><td headers="hd_h_niceng220er4.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=29)</p>
|
|
<p>Amantadine 100mg orally twice a day for 4 weeks</p>
|
|
<p>Placebo (n=29)</p>
|
|
<p>Concomitant therapy:</p>
|
|
<p>No additional information</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 29</p>
|
|
<p>Age (mean [SD]): 44.5 (9.3) years</p>
|
|
<p>Type of multiple sclerosis: 13 demonstrated a chronic deteriorating or relapsing/deteriorating course of illness, while 16 exhibited either a benign or remitting/relapsing course.</p>
|
|
<p>EDSS: <6 (people with a score >6 were excluded)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Withdrawal due to adverse events at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>This study was a crossover trial (two-week washout).</p>
|
|
<p>This study was included in the previous version of the guideline.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Krupp 1995<a class="bibr" href="#niceng220er4.s1.1.ref13" rid="niceng220er4.s1.1.ref13"><sup>13</sup></a></p>
|
|
<p>Subsidiary studies: Geisler 1996<a class="bibr" href="#niceng220er4.s1.1.ref11" rid="niceng220er4.s1.1.ref11"><sup>11</sup></a></p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=31)</p>
|
|
<p>Amantadine 100mg twice a day for 2 months</p>
|
|
<p>Placebo (n=35)</p>
|
|
<p>A third group receiving pemoline (n=27) was not included in this review as they did not fulfil the inclusion criteria in the protocol.</p>
|
|
<p>Concomitant therapy: No additional information.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 93</p>
|
|
<p>Age (mean [SD]): 41.1 (6.5) years</p>
|
|
<p>Type of multiple sclerosis: 90–94% had relapsing-remitting multiple sclerosis</p>
|
|
<p>EDSS: 2.38 (1.54)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Withdrawal due to adverse events at 3–6 months</p>
|
|
<p>Sleep disturbance at 3–6 months</p>
|
|
<p>Cardiac disorder/arrhythmia at 3–6 months</p>
|
|
<p>Cognitive functions at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The patient-reported outcome measures to assess MS fatigue and cognitive functions outcomes were extracted from Geisler 1996 which only included a subset of the participants included in the original Krupp study (as these values were only reported in a manner that could be meta-analysed in the Geisler study).</p>
|
|
<p>This study was included in the previous version of the guideline. In the previous version of the guideline these studies were reported separately. Due to the participants in the Geisler study being a subset of those from the Krupp study, they were combined in this analysis for this version.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ledinek 2013<a class="bibr" href="#niceng220er4.s1.1.ref14" rid="niceng220er4.s1.1.ref14"><sup>14</sup></a></td><td headers="hd_h_niceng220er4.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=15)</p>
|
|
<p>Amantadine 200mg orally daily for 1 month</p>
|
|
<p>Modafinil (n=15)</p>
|
|
<p>Modafinil 200mg orally daily for 1 month</p>
|
|
<p>Placebo (n=15)</p>
|
|
<p>A fourth group receiving acetyl-l-carnitine (n=15) was not extracted as it did not fulfil the inclusion criteria in the protocol.</p>
|
|
<p>Concomitant therapy: No additional information.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 60</p>
|
|
<p>Age (mean [SD]): 38.0 (6.1) years</p>
|
|
<p>Type of multiple sclerosis: Not stated/unclear.</p>
|
|
<p>EDSS: 2.7 (1.1)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Health-related Quality of Life at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was included in the previous version of the guideline.</td></tr><tr><td headers="hd_h_niceng220er4.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Murray 1985<a class="bibr" href="#niceng220er4.s1.1.ref16" rid="niceng220er4.s1.1.ref16"><sup>16</sup></a></td><td headers="hd_h_niceng220er4.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=32)</p>
|
|
<p>Amantadine 100mg orally twice a day for 3 weeks, then placebo orally twice a day for 3 weeks (1 week washout period between doses)</p>
|
|
<p>Placebo (n=32)</p>
|
|
<p>Concomitant therapy: Not stated/unclear.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 32</p>
|
|
<p>Age (mean [SD]): Not stated/unclear.</p>
|
|
<p>Type of multiple sclerosis: Not stated/unclear.</p>
|
|
<p>EDSS: Most of the participants were in the 0–3 range in the EDSS.</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events at 3–6 months</td><td headers="hd_h_niceng220er4.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>This study was a crossover trial (1 week washout).</p>
|
|
<p>This study was included in the previous version of the guideline.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Nourbakhsh 2021<a class="bibr" href="#niceng220er4.s1.1.ref19" rid="niceng220er4.s1.1.ref19"><sup>19</sup></a> (TRIUMPHANT-MS)</p>
|
|
<p>Subsidiary studies: Nourbakhsh 2018<a class="bibr" href="#niceng220er4.s1.1.ref20" rid="niceng220er4.s1.1.ref20"><sup>20</sup></a></p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=141)</p>
|
|
<p>Oral amantadine (up to 100mg twice daily)</p>
|
|
<p>Modafinil (n=141)</p>
|
|
<p>Oral modafinil (up to 100mg twice daily)</p>
|
|
<p>Placebo (n=141)</p>
|
|
<p>A fourth group receiving methylphenidate (n=141) was reported. The results for this group was not extracted as they did not fulfil the inclusion criteria in the protocol.</p>
|
|
<p>Concomitant therapy: Not stated/unclear.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 141</p>
|
|
<p>Age (mean [SD]): 46.8 (10.7) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting MS: 106</p>
|
|
<p>Secondary progressive MS: 19</p>
|
|
<p>Primary progressive MS: 15.</p>
|
|
<p>EDSS (median [IQR]): 3 (2–4.5)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Withdrawal due to adverse events at 3–6 months</p>
|
|
<p>Cardiac events/arrhythmia at 3–6 months</p>
|
|
<p>Epworth Sleepiness scale at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a href="http://Clinicaltrials.gov" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Clinicaltrials<wbr style="display:inline-block"></wbr>​.gov</a> number: <a href="https://clinicaltrials.gov/show/NCT03185065" title="Study NCT03185065" ref="pagearea=body&targetsite=external&targetcat=link&targettype=clinical-trial">NCT03185065</a>.</p>
|
|
<p>This study was a crossover trial (2-week washout).</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rocca 2021<a class="bibr" href="#niceng220er4.s1.1.ref22" rid="niceng220er4.s1.1.ref22"><sup>22</sup></a></td><td headers="hd_h_niceng220er4.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=15)</p>
|
|
<p>Oral amantadine (100mg twice daily for 4 weeks)</p>
|
|
<p>Placebo (n=15)</p>
|
|
<p>(One placebo tablet twice daily for 4 weeks)</p>
|
|
<p>A third group receiving fampridine (n=15) was reported but not extracted as this was not an intervention in the review protocol.</p>
|
|
<p>Concomitant therapy: Not stated/unclear.</p>
|
|
<p>Disease modifying treatment status: majority (>80%) were taking these treatments</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 30</p>
|
|
<p>Age (mean [IQR]): 41.2 (34–46) years in amantadine and 41.9 (33–49) years in placebo</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting MS: all relapsing remitting (inclusion criterion)</p>
|
|
<p>EDSS (median [IQR]): 2.5 (2 to 2.5) in amantadine group and 2 (1.5 to 2) in placebo group</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Withdrawal due to adverse events at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Trial registration: EudraCT 2010-023678-38.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab5"><div id="niceng220er4.tab5" class="table"><h3><span class="label">Table 5</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab5_lrgtbl__"><table><thead><tr><th id="hd_h_niceng220er4.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng220er4.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention and comparison</th><th id="hd_h_niceng220er4.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng220er4.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Cambron 2019<a class="bibr" href="#niceng220er4.s1.1.ref4" rid="niceng220er4.s1.1.ref4"><sup>4</sup></a></p>
|
|
<p>(FLUOX-PMS trial)</p>
|
|
<p>Subsidiary studies: Cambron 2016<a class="bibr" href="#niceng220er4.s1.1.ref5" rid="niceng220er4.s1.1.ref5"><sup>5</sup></a></p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Fluoxetine (n=74)</p>
|
|
<p>Fluoxetine 20mg orally for 4 weeks, followed by a daily single intake of 2 tablets of 20mg fluoxetine until week 108.</p>
|
|
<p>Placebo (n=77)</p>
|
|
<p>Concomitant therapy: Concomitant medications that could lead to clinically significant interactions with fluoxetine (such as monoamine oxidase inhibitors) were not allowed. The use of interferon beta or glatiramer acetate was allowed, as these drugs are ineffective in slowing down disability accrual in progressive MS. Patients using other immunosuppressive or immunomodulatory drugs could only be included if the drug was stopped at least for 2 months before randomisation.</p>
|
|
<p>Disease modifying treatment status: People were allowed to use some treatment (see concomitant therapies). However, only around 27% received them.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 151</p>
|
|
<p>Age (mean [SD]): 52.6 (7.1) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Primary progressive MS: 77</p>
|
|
<p>Secondary progressive MS: 55</p>
|
|
<p>EDSS (mean [SD]): 13.3 (8.4)</p>
|
|
<p>People receiving palliative care: Not stated/unclear</p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at >6 months-1 year</p>
|
|
<p>Adverse events leading to withdrawal at >6 months-1 year</p>
|
|
<p>Disruption to sleep at >6 months-1 year</p>
|
|
<p>Cognitive functions at >6 months-1 year</p>
|
|
<p>Psychological symptoms at >6 months-1 year</p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EudraCT Number 2011-003775-11.</td></tr><tr><td headers="hd_h_niceng220er4.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Chataway 2020<a class="bibr" href="#niceng220er4.s1.1.ref7" rid="niceng220er4.s1.1.ref7"><sup>7</sup></a> (MS-SMART trial)</p>
|
|
<p>Subsidiary studies: Chataway 2015<a class="bibr" href="#niceng220er4.s1.1.ref6" rid="niceng220er4.s1.1.ref6"><sup>6</sup></a></p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Fluoxetine (n=111)</p>
|
|
<p>Fluoxetine 20mg orally once a day for 4 weeks, then twice a day from week 4 to week 96.</p>
|
|
<p>Placebo (n=112)</p>
|
|
<p>Two additional groups were reported in the study reporting participants receiving amiloride and riluzole (both n=111). These were excluded from this review as they were not included in the protocol.</p>
|
|
<p>Concomitant therapy: No additional information.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 445</p>
|
|
<p>Age (mean [95% CI]):</p>
|
|
<p>Fluoxetine: 55.5 (50.7 to 60.2) years</p>
|
|
<p>Placebo: 56.4 (49.2 to 60.4) years</p>
|
|
<p>Type of multiple sclerosis: Secondary progressive multiple sclerosis.</p>
|
|
<p>EDSS (mean [95% CI]):</p>
|
|
<p>Fluoxetine: 6 (5.5 to 6.5)</p>
|
|
<p>Placebo: 6 (5.5 to 6.5)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at >6 months-1 year</p>
|
|
<p>Cardiac events/arrhythmia at >6 months-1 year</p>
|
|
<p>Health-related Quality of Life at >6 months-1 year</p>
|
|
<p>Cognitive functions at >6 months-1 year</p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="http://Clinicaltrials.gov" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ClinicialTrials<wbr style="display:inline-block"></wbr>​.gov</a> registry = <a href="https://clinicaltrials.gov/show/NCT01910259" title="Study NCT01910259" ref="pagearea=body&targetsite=external&targetcat=link&targettype=clinical-trial">NCT01910259</a>.</td></tr><tr><td headers="hd_h_niceng220er4.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Edhe 2008<a class="bibr" href="#niceng220er4.s1.1.ref9" rid="niceng220er4.s1.1.ref9"><sup>9</sup></a></td><td headers="hd_h_niceng220er4.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Paroxetine (n=22)</p>
|
|
<p>Paroxetine 10mg per day, up titrated to 20mg/day after 1 week (2 capsules) and then could be further up titrated a maximum of 40mg/day in subsequent weeks dependent on symptoms or down titrated due to adverse events.</p>
|
|
<p>Placebo (n=20)</p>
|
|
<p>Concomitant therapy: No additional information.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 42</p>
|
|
<p>Age (mean [SD]): 45 (10.1) years</p>
|
|
<p>Type of multiple sclerosis: Not stated/unclear.</p>
|
|
<p>EDSS: Mixed. Mild (0–4): 22, Moderate (4.5–6.5): 16, Severe (8–9.5): 4.</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Withdrawal due to adverse events at 3–6 months</p>
|
|
<p>Health-related Quality of Life at 3–6 months</p>
|
|
<p>Cognitive functions at 3–6 months</p>
|
|
<p>Psychological symptoms at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was included in the previous version of the guideline.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab6"><div id="niceng220er4.tab6" class="table"><h3><span class="label">Table 6</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab6_lrgtbl__"><table><thead><tr><th id="hd_h_niceng220er4.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng220er4.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention and comparison</th><th id="hd_h_niceng220er4.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng220er4.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sadeghi-Naini 2017<a class="bibr" href="#niceng220er4.s1.1.ref24" rid="niceng220er4.s1.1.ref24"><sup>24</sup></a></td><td headers="hd_h_niceng220er4.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Aspirin (n=64)</p>
|
|
<p>Oral low dose aspirin (80mg) daily for 8 weeks</p>
|
|
<p>Placebo (n=56)</p>
|
|
<p>Concomitant therapy: All people were using the different disease modifying therapies including beta-interferons which were prescribed for them.</p>
|
|
<p>Disease modifying treatment status: All participants were receiving disease modifying therapy.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 120</p>
|
|
<p>Age (mean [SD]): 33.2 (9.1) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting MS: 80</p>
|
|
<p>Secondary progressive MS: 18</p>
|
|
<p>Primary progressive MS: 2</p>
|
|
<p>EDSS: 1.8 (1.2)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events at 3–6 months</td><td headers="hd_h_niceng220er4.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab7"><div id="niceng220er4.tab7" class="table"><h3><span class="label">Table 7</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab7_lrgtbl__"><table><thead><tr><th id="hd_h_niceng220er4.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng220er4.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention and comparison</th><th id="hd_h_niceng220er4.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng220er4.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ford-Johnson 2016<a class="bibr" href="#niceng220er4.s1.1.ref10" rid="niceng220er4.s1.1.ref10"><sup>10</sup></a></td><td headers="hd_h_niceng220er4.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Modafinil (n=9)</p>
|
|
<p>Modafinil 200mg once a day orally for 2 weeks, followed by 1 week washout, then placebo once a day orally for 2 weeks.</p>
|
|
<p>Placebo (n=9)</p>
|
|
<p>Concomitant therapy: No additional information.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 18</p>
|
|
<p>Age (mean [SD]): 42.44 (8.06) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting: 10</p>
|
|
<p>Primary progressive: 1</p>
|
|
<p>Secondary progressive: 3</p>
|
|
<p>Progressive relapsing: 0</p>
|
|
<p>Unknown: 2</p>
|
|
<p>EDSS: 3.9 (2.2)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Withdrawal due to adverse events at 3–6 months</p>
|
|
<p>Health-related Quality of Life at 3–6 months</p>
|
|
<p>Cognitive functions at 3–6 months</p>
|
|
<p>Psychological symptoms at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="http://Clinicaltrials.gov" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Clinicaltrials<wbr style="display:inline-block"></wbr>​.gov</a> - <a href="https://clinicaltrials.gov/show/NCT00142402" title="Study NCT00142402" ref="pagearea=body&targetsite=external&targetcat=link&targettype=clinical-trial">NCT00142402</a>.</td></tr><tr><td headers="hd_h_niceng220er4.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ledinek 2013<a class="bibr" href="#niceng220er4.s1.1.ref14" rid="niceng220er4.s1.1.ref14"><sup>14</sup></a></td><td headers="hd_h_niceng220er4.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=15)</p>
|
|
<p>Amantadine 200mg orally daily for 1 month</p>
|
|
<p>Modafinil (n=15)</p>
|
|
<p>Modafinil 200mg orally daily for 1 month</p>
|
|
<p>Placebo (n=15)</p>
|
|
<p>A fourth group receiving acetyl-l-carnitine (n=15) was not extracted as it did not fulfil the inclusion criteria in the protocol.</p>
|
|
<p>Concomitant therapy: No additional information.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 60</p>
|
|
<p>Age (mean [SD]): 38.0 (6.1) years</p>
|
|
<p>Type of multiple sclerosis: Not stated/unclear.</p>
|
|
<p>EDSS: 2.7 (1.1)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Health-related Quality of Life at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was included in the previous version of the guideline.</td></tr><tr><td headers="hd_h_niceng220er4.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Möller 2011<a class="bibr" href="#niceng220er4.s1.1.ref15" rid="niceng220er4.s1.1.ref15"><sup>15</sup></a> (HAGIL study)</td><td headers="hd_h_niceng220er4.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Modafinil (n=62)</p>
|
|
<p>Modafinil oral 200mg/day up titrated over 1 week, then continued for 8 weeks in total.</p>
|
|
<p>Placebo (n=59)</p>
|
|
<p>Concomitant therapy: Not stated/unclear.</p>
|
|
<p>Disease modifying treatment status: Mixed. 50.4% were on immunotherapy.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 121</p>
|
|
<p>Age (mean [SD]): 41.1 (10.3) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting MS: 63</p>
|
|
<p>Secondary-progressive MS: 31</p>
|
|
<p>Primary-progressive MS: 26.</p>
|
|
<p>EDSS: 3.3 (1.4).</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Health-related Quality of Lfe at 3–6 months</p>
|
|
<p>Epworth Sleepiness scale at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng220er4.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Nourbakhsh 2021<a class="bibr" href="#niceng220er4.s1.1.ref19" rid="niceng220er4.s1.1.ref19"><sup>19</sup></a></p>
|
|
<p>Subsidiary studies: Nourbakhsh 2018<a class="bibr" href="#niceng220er4.s1.1.ref20" rid="niceng220er4.s1.1.ref20"><sup>20</sup></a></p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Amantadine (n=141)</p>
|
|
<p>Oral amantadine (up to 100mg twice daily)</p>
|
|
<p>Modafinil (n=141)</p>
|
|
<p>Oral modafinil (up to 100mg twice daily)</p>
|
|
<p>Placebo (n=141)</p>
|
|
<p>A fourth group receiving methylphenidate (n=141) was reported. The results for this group was not extracted as they did not fulfil the inclusion criteria in the protocol.</p>
|
|
<p>Concomitant therapy: Not stated/unclear.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 141</p>
|
|
<p>Age (mean [SD]): 46.8 (10.7) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting MS: 106</p>
|
|
<p>Secondary progressive MS: 19</p>
|
|
<p>Primary progressive MS: 15.</p>
|
|
<p>EDSS (median [IQR]): 3 (2–4.5)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS fatigue at 3–6 months</p>
|
|
<p>Withdrawal due to adverse events at 3–6 months</p>
|
|
<p>Cardiac events/arrhythmia at 3–6 months</p>
|
|
<p>Epworth Sleepiness scale at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><a href="http://Clinicaltrials.gov" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Clinicaltrials<wbr style="display:inline-block"></wbr>​.gov</a> number: <a href="https://clinicaltrials.gov/show/NCT03185065" title="Study NCT03185065" ref="pagearea=body&targetsite=external&targetcat=link&targettype=clinical-trial">NCT03185065</a>.</p>
|
|
<p>This study was a crossover trial (two-week washout).</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stankoff 2005<a class="bibr" href="#niceng220er4.s1.1.ref26" rid="niceng220er4.s1.1.ref26"><sup>26</sup></a></td><td headers="hd_h_niceng220er4.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Modafinil (n=59)</p>
|
|
<p>Oral modafinil 200mg for 1 week, increased by 100mg every week up to 400mg/day and remaining at that dose between day 31 and day 35 (5 weeks treatment in total).</p>
|
|
<p>Placebo (n=56)</p>
|
|
<p>Concomitant therapy: Disease-modifying therapies such as beta interferon, glatiramer acetate, azathioprine or methotrexate were allowed, but had to be a stable dose for at least 6 months before treatment. All symptomatic treatment for fatigue had to be withdrawn at least 14 days before randomisation.</p>
|
|
<p>Disease modifying treatment status: Unclear. People were allowed to continue previous treatment.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 115</p>
|
|
<p>Age (mean [SD]): 43.9 (8.5) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting or progressive MS.</p>
|
|
<p>EDSS (mean [SD]): 3.5 (1.7)</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patient-reported outcome measures to assess MS at 3–6 months</p>
|
|
<p>Withdrawal due to adverse events at 3–6 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab8"><div id="niceng220er4.tab8" class="table"><h3><span class="label">Table 8</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab8_lrgtbl__"><table><thead><tr><th id="hd_h_niceng220er4.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng220er4.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention and comparison</th><th id="hd_h_niceng220er4.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng220er4.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hamzei-Moghaddam 2011<a class="bibr" href="#niceng220er4.s1.1.ref12" rid="niceng220er4.s1.1.ref12"><sup>12</sup></a></td><td headers="hd_h_niceng220er4.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Combination of pharmacological therapies (amantadine and aspirin) (n=21)</p>
|
|
<p>Amantadine 100mg and aspirin 500mg twice a day for 6 weeks.</p>
|
|
<p>Amantadine (n=24)</p>
|
|
<p>Amantadine 100mg and placebo twice a day for 6 weeks.</p>
|
|
<p>Concomitant therapy: No additional information.</p>
|
|
<p>Disease modifying treatment status: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Multiple Sclerosis</p>
|
|
<p>N = 45</p>
|
|
<p>Age (mean [SD]): 33.1 (7.5) years</p>
|
|
<p>Type of multiple sclerosis:</p>
|
|
<p>Relapsing-remitting: 36. Secondary progressive: 9.</p>
|
|
<p>EDSS: Mixed</p>
|
|
<p>EDSS <2: 13.</p>
|
|
<p>EDSS 2–5: 14.</p>
|
|
<p>EDSS >5: 18.</p>
|
|
<p>People receiving palliative care: Not stated/unclear.</p>
|
|
</td><td headers="hd_h_niceng220er4.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue at 3–6 months</td><td headers="hd_h_niceng220er4.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Iranian Randomised Clinical trial number: 201112208430N3.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab9"><div id="niceng220er4.tab9" class="table"><h3><span class="label">Table 9</span><span class="title">Clinical evidence summary: amantadine compared to aspirin</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng220er4.tab9_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab9_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab9_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab9_1_1_1_2" style="text-align:left;vertical-align:bottom;">№ of participants (studies) Follow up</th><th id="hd_h_niceng220er4.tab9_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab9_1_1_1_3" style="text-align:left;vertical-align:bottom;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng220er4.tab9_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab9_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng220er4.tab9_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng220er4.tab9_1_1_1_5" id="hd_h_niceng220er4.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with aspirin</th><th headers="hd_h_niceng220er4.tab9_1_1_1_5" id="hd_h_niceng220er4.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with amantadine</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (FSS, 1–7, lower values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>52</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 10 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab9_1_1_1_5 hd_h_niceng220er4.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 3.55</td><td headers="hd_h_niceng220er4.tab9_1_1_1_5 hd_h_niceng220er4.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.2 higher</b>
|
|
</p>
|
|
<p>(0.63 lower to 1.03 higher)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng220er4.tab9_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng220er4.tab9_2"><p class="no_margin">Downgraded by 1 or 2 increments because of outcome indirectness</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng220er4.tab9_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab10"><div id="niceng220er4.tab10" class="table"><h3><span class="label">Table 10</span><span class="title">Clinical evidence summary: amantadine compared to modafinil</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab10_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng220er4.tab10_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab10_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab10_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab10_1_1_1_2" style="text-align:left;vertical-align:bottom;">№ of participants (studies) Follow up</th><th id="hd_h_niceng220er4.tab10_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab10_1_1_1_3" style="text-align:left;vertical-align:bottom;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng220er4.tab10_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab10_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng220er4.tab10_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng220er4.tab10_1_1_1_5" id="hd_h_niceng220er4.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with modafinil</th><th headers="hd_h_niceng220er4.tab10_1_1_1_5" id="hd_h_niceng220er4.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with amantadine</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (MFIS, 0–84, lower values are better, final value, parallel trial and crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>278</p>
|
|
<p>(2 RCTs)</p>
|
|
<p>follow up: mean 5 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 7.51 lower</b>
|
|
</p>
|
|
<p>(27.58 lower to 12.56 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events at 3–6 months (crossover)</td><td headers="hd_h_niceng220er4.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>252</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 6 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>c</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 2.95</p>
|
|
<p>(0.31 to 28.01)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 per 1,000</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>16 more per 1,000</b>
|
|
</p>
|
|
<p>(6 fewer to 216 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardiac events/arrhythmias at 3–6 months (crossover)</td><td headers="hd_h_niceng220er4.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>252</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 6 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>c</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.59</p>
|
|
<p>(0.14 to 2.42)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40 per 1,000</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>16 fewer per 1,000</b>
|
|
</p>
|
|
<p>(34 fewer to 57 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (SF-36 physical component summary, 0–100, higher values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>30</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>c</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 41.5</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 7.1 lower</b>
|
|
</p>
|
|
<p>(12.21 lower to 1.99 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (SF-36 mental component summary, 0–100, higher values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>30</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>c</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 42.8</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 6 higher</b>
|
|
</p>
|
|
<p>(1.01 higher to 10.99 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Epworth Sleepiness scale (0–24, lower values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>248</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 6 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕◯◯</p>
|
|
<p>LOW<sup>a</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean Epworth Sleepiness scale was 8.3</td><td headers="hd_h_niceng220er4.tab10_1_1_1_5 hd_h_niceng220er4.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD <b>1 higher</b></p>
|
|
<p>(0.02 higher to 1.98 higher)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng220er4.tab10_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng220er4.tab10_2"><p class="no_margin">Downgraded by 1 or 2 increments because heterogeneity, unexplained by subgroup analysis</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng220er4.tab10_3"><p class="no_margin">Downgraded by 1 or 2 increments because of outcome indirectness</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng220er4.tab10_4"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab11"><div id="niceng220er4.tab11" class="table"><h3><span class="label">Table 11</span><span class="title">Clinical evidence summary: amantadine compared to placebo</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab11_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab11_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab11_1_1_1_2" style="text-align:left;vertical-align:bottom;">№ of participants (studies) Follow up</th><th id="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab11_1_1_1_3" style="text-align:left;vertical-align:bottom;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab11_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng220er4.tab11_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng220er4.tab11_1_1_1_5" id="hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with placebo</th><th headers="hd_h_niceng220er4.tab11_1_1_1_5" id="hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with amantadine</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (FSS, 1–7, lower values are better, change score and final value, parallel trials) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>74</p>
|
|
<p>(2 RCTs) follow up: mean 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 3.03</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.56 lower</b>
|
|
</p>
|
|
<p>(0.81 lower to 0.31 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (MFIS, 0–84, lower values are better, final value, parallel trial and crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>307</p>
|
|
<p>(3 RCTs)</p>
|
|
<p>follow up: mean 5 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup><sup>,</sup><sup>d</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 3.57 lower</b>
|
|
</p>
|
|
<p>(15.06 lower to 7.91 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (diary ratings of fatigue - energy level, 1–5, higher values are better, final values, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>44</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 10 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 2.76</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.28 higher</b>
|
|
</p>
|
|
<p>(0.06 higher to 0.5 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (diary ratings of fatigue - muscle strength, 1–5, higher values are better, final values, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>44</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 10 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 2.75</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.19 higher</b>
|
|
</p>
|
|
<p>(0.03 lower to 0.41 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (diary ratings of fatigue - concentration/memory, 1–5, higher values are better, final values, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>44</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 10 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 2.98</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.42 higher</b>
|
|
</p>
|
|
<p>(0.18 higher to 0.66 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (diary ratings of fatigue - motivation level, 1–5, higher values are better, final values, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>44</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 10 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 2.98</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.18 higher</b>
|
|
</p>
|
|
<p>(0.06 lower to 0.42 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (diary ratings of fatigue - ability to finish task, 1–5, higher values are better, final values, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>44</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 10 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 3.02</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.14 higher</b>
|
|
</p>
|
|
<p>(0.1 lower to 0.38 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (diary ratings of fatigue - ability to solve problem, 1–5, higher values are better, final values, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>44</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 10 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 3.13</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.24 higher</b>
|
|
</p>
|
|
<p>(0.02 lower to 0.5 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (diary ratings of fatigue - wellbeing, 1–5, higher values are better, final values, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>44</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 10 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 2.9</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.27 higher</b>
|
|
</p>
|
|
<p>(0.07 higher to 0.47 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events leading to withdrawal at 3–6 months (parallel trial and crossover trials)</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>741</p>
|
|
<p>(7 RCTs)</p>
|
|
<p>follow up: mean 7 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>e</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RD 0.00</p>
|
|
<p>(−0.02 to 0.02)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0 per 1,000</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>0 fewer per 1,000</b>
|
|
</p>
|
|
<p>(20 fewer to 20 more)<sup>g</sup></p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Disruption of sleep at 3–6 months (parallel trial and crossover trial)</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>296</p>
|
|
<p>(2 RCTs)</p>
|
|
<p>follow up: mean 6 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.81</p>
|
|
<p>(1.11 to 2.94)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">133 per 1,000</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>108 more per 1,000</b>
|
|
</p>
|
|
<p>(15 more to 259 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardiac events/arrhythmias at 3–6 months (parallel trial and crossover trials)</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>547</p>
|
|
<p>(3 RCTs)</p>
|
|
<p>follow up: mean 6 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>e</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RD 0.00</p>
|
|
<p>(−0.01 to 0.02)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0 per 1,000</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>0 fewer per 1,000</b>
|
|
</p>
|
|
<p>(10 fewer to 20 more)<sup>g</sup></p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (SF-36 physical component summary, 0–100, higher values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>30</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 41.5</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 7.1 lower</b>
|
|
</p>
|
|
<p>(12.21 lower to 1.99 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (SF-36 mental component summary, 0–100, higher values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>30</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 40.4</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 8.4 higher</b>
|
|
</p>
|
|
<p>(2.9 higher to 13.9 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (13-item activities of daily living intellectual function factor, 0–50, lower values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>172</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 3 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 8.25</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.58 lower</b>
|
|
</p>
|
|
<p>(1.54 lower to 0.38 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (selective reminding - long-term retrieval, higher values are better, final value) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>32</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 45.2</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 3 lower</b>
|
|
</p>
|
|
<p>(13.23 lower to 7.23 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (selective reminding - delayed recall, higher values are better, final value) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>32</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 8.9</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0</b>
|
|
</p>
|
|
<p>(2.33 lower to 2.33 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (selective reminding - sum of recall, higher values are better, final value) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>32</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 53.5</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 1.2 lower</b>
|
|
</p>
|
|
<p>(7.14 lower to 4.74 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (Benton Visual Retention, lower values are better, final value) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>32</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 2.8</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 1.5 higher</b>
|
|
</p>
|
|
<p>(0.03 higher to 2.97 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (WAIS-R Digit Span, higher values are better, final value) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>32</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 16.5</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.9 lower</b>
|
|
</p>
|
|
<p>(3.07 lower to 1.27 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (Trail Making Test - Part A, lower values are better, final value) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>32</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 36.2</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 5.3 lower</b>
|
|
</p>
|
|
<p>(13.64 lower to 3.04 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (Trail Making Test - Part B, lower values are better, final value) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>32</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 83.1</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 14.2 lower</b>
|
|
</p>
|
|
<p>(35.14 lower to 6.74 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (symbol digit modalities test - written, higher values are better, final value) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>32</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 46.6</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 2 higher</b>
|
|
</p>
|
|
<p>(8.37 lower to 12.37 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (symbol digit modalities test - oral, higher values are better, final value) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>32</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 58.3</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.5 lower</b>
|
|
</p>
|
|
<p>(13.19 lower to 12.19 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Psychological symptoms (Beck Depression Inventory, 0–63, lower values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>172</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 3 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean psychological symptoms was 7.59</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.25 lower</b>
|
|
</p>
|
|
<p>(2.54 lower to 2.04 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Epworth Sleepiness scale (0–24, lower values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>247</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 6 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⨁◯◯</p>
|
|
<p>LOW<sup>a</sup><sup>,</sup><sup>b</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean Epworth Sleepiness scale was 9.4</td><td headers="hd_h_niceng220er4.tab11_1_1_1_5 hd_h_niceng220er4.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.1 lower</b>
|
|
</p>
|
|
<p>(1.08 lower to 0.88 higher)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng220er4.tab11_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng220er4.tab11_2"><p class="no_margin">Downgraded by 1 or 2 increments because of outcome indirectness</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng220er4.tab11_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng220er4.tab11_4"><p class="no_margin">Downgraded by 1 or 2 increments because heterogeneity, unexplained by subgroup analysis</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng220er4.tab11_5"><p class="no_margin">Downgraded for heterogeneity due to conflicting number of events in different studies (zero events in one or more studies)</p></div></dd></dl><dl class="bkr_refwrap"><dt>f</dt><dd><div id="niceng220er4.tab11_6"><p class="no_margin">Downgraded by 1 to 2 increments for imprecision due to zero events and small sample size</p></div></dd></dl><dl class="bkr_refwrap"><dt>g</dt><dd><div id="niceng220er4.tab11_7"><p class="no_margin">Absolute effect calculated by risk difference due to zero events in at least one arm of one study</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab12"><div id="niceng220er4.tab12" class="table"><h3><span class="label">Table 12</span><span class="title">Clinical evidence summary: SSRIs compared to placebo</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab12/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab12_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab12_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab12_1_1_1_2" style="text-align:left;vertical-align:bottom;">№ of participants (studies) Follow up</th><th id="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab12_1_1_1_3" style="text-align:left;vertical-align:bottom;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab12_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng220er4.tab12_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng220er4.tab12_1_1_1_5" id="hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with placebo</th><th headers="hd_h_niceng220er4.tab12_1_1_1_5" id="hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with SSRIs</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (MFIS, 0–84, lower values are better, final value) at 3–6 months</td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>42</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 52.1</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 12.8 lower</b>
|
|
</p>
|
|
<p>(22.93 lower to 2.67 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (Modified fatigue impact scale, Neurological Fatigue Index Summary Score [different scale ranges], lower values are better, final values, parallel trials) at >6 months-1 year</td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>328</p>
|
|
<p>(2 RCTs)</p>
|
|
<p>follow up: mean 54 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊕</p>
|
|
<p>HIGH</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>SMD 0.16 higher</b>
|
|
</p>
|
|
<p>(0.06 lower to 0.37 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events leading to withdrawal at >6 months-1 year (parallel trial)<sup>d</sup></td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>137</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 60 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.70</p>
|
|
<p>(0.23 to 2.11)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">103 per 1,000</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>31 fewer per 1,000</b>
|
|
</p>
|
|
<p>(79 fewer to 114 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Disruption to sleep at >6 months-1 year (parallel trial)<sup>d</sup></td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>137</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 60 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕◯</p>
|
|
<p>MODERATE<sup>a</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>OR 7.28</p>
|
|
<p>(0.14 to 367.07)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0 per 1,000</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>10 more per 1,000</b>
|
|
</p>
|
|
<p>(20 fewer to 50 more)<sup>e</sup></p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardiac events/arrhythmias at >6 months-1 year (parallel trial)</td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>223</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 96 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕◯◯</p>
|
|
<p>LOW<sup>c</sup><sup>,</sup><sup>f</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.51</p>
|
|
<p>(0.26 to 8.88)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 per 1,000</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>9 more per 1,000</b>
|
|
</p>
|
|
<p>(13 fewer to 141 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (SF-36 physical component summary, 0–100, higher values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>42</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 35.5</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.9 higher</b>
|
|
</p>
|
|
<p>(6.87 lower to 8.67 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (SF-36 mental component summary, 0–100, higher values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>42</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 42.5</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 5.9 higher</b>
|
|
</p>
|
|
<p>(8.25 lower to 20.05 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (EQ-5D-5L utility index score, −0.1–11, higher values are better, final value, parallel trial) at >6 months-1 year</td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>194</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 48 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕◯◯</p>
|
|
<p>LOW<sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 0.65</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.01 higher</b>
|
|
</p>
|
|
<p>(0.04 lower to 0.06 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (EQ-5D-5L visual analogue scale score, 0–100, higher values are better, final value, parallel trial) at >6 months-1 year</td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>194</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 48 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊕</p>
|
|
<p>HIGH</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 62.96</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 3.18 higher</b>
|
|
</p>
|
|
<p>(2.6 lower to 8.96 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (PDQ, 0–100, lower values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>42</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 40.4</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 11.3 lower</b>
|
|
</p>
|
|
<p>(19.1 lower to 3.5 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (Symbol digit modalities test, higher values are better, final value, parallel trials) at >6 months-1 year</td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>328</p>
|
|
<p>(2 RCTs)</p>
|
|
<p>follow up: mean 54 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊕</p>
|
|
<p>HIGH</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 41.0</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.77 lower</b>
|
|
</p>
|
|
<p>(3.42 lower to 1.88 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (California verbal learning test-II, higher values are better, final value, parallel trial) at >6 months-1 year<sup>d</sup></td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>134</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 60 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕◯</p>
|
|
<p>MODERATE<sup>a</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 137</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.5 higher</b>
|
|
</p>
|
|
<p>(8.98 lower to 9.98 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (Controlled oral word association test - semantic, higher values are better, final value, parallel trial) at >6 months-1 year<sup>d</sup></td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>134</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 60 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕◯</p>
|
|
<p>MODERATE<sup>a</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 20</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.4 higher</b>
|
|
</p>
|
|
<p>(1.63 lower to 2.43 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (Controlled oral word association test - phonetic, higher values are better, final value, parallel trial) at >6 months-1 year<sup>d</sup></td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>134</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 60 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕◯◯</p>
|
|
<p>LOW<sup>a</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 29.1</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 5.5 higher</b>
|
|
</p>
|
|
<p>(1.54 higher to 9.46 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Psychological symptoms (HAM-D, 0–50, lower values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>42</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean psychological symptoms was 10.9</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 4.5 lower</b>
|
|
</p>
|
|
<p>(7.29 lower to 1.71 lower)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Psychological symptoms (Beck depression inventory-II, 0–63, lower values are better, final values, parallel trial) at >6 months-1 year<sup>d</sup></td><td headers="hd_h_niceng220er4.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>134</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 60 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕◯◯</p>
|
|
<p>LOW<sup>a</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean psychological symptoms was 11.3</td><td headers="hd_h_niceng220er4.tab12_1_1_1_5 hd_h_niceng220er4.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.6 higher</b>
|
|
</p>
|
|
<p>(2.1 lower to 3.3 higher)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng220er4.tab12_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng220er4.tab12_2"><p class="no_margin">Downgraded by 1 or 2 increments because of population indirectness</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng220er4.tab12_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng220er4.tab12_4"><p class="no_margin">This is not downgraded for indirectness as there was a period of 4 weeks where the fluoxetine dose was titrated up that was included in this follow up period. Therefore, the follow up is essentially 1 year.</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng220er4.tab12_5"><p class="no_margin">Absolute effect calculated by risk difference due to zero events in at least one arm of one study</p></div></dd></dl><dl class="bkr_refwrap"><dt>f</dt><dd><div id="niceng220er4.tab12_6"><p class="no_margin">Downgraded by 1 or 2 increments due to outcome indirectness</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab13"><div id="niceng220er4.tab13" class="table"><h3><span class="label">Table 13</span><span class="title">Clinical evidence summary: aspirin compared to placebo</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab13/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab13_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng220er4.tab13_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab13_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab13_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab13_1_1_1_2" style="text-align:left;vertical-align:bottom;">№ of participants (studies) Follow up</th><th id="hd_h_niceng220er4.tab13_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab13_1_1_1_3" style="text-align:left;vertical-align:bottom;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng220er4.tab13_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab13_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng220er4.tab13_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng220er4.tab13_1_1_1_5" id="hd_h_niceng220er4.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with placebo</th><th headers="hd_h_niceng220er4.tab13_1_1_1_5" id="hd_h_niceng220er4.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with aspirin</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events at 3–6 months (parallel trial)</td><td headers="hd_h_niceng220er4.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>120</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 8 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.46</p>
|
|
<p>(0.36 to 5.83)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab13_1_1_1_5 hd_h_niceng220er4.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54 per 1,000</td><td headers="hd_h_niceng220er4.tab13_1_1_1_5 hd_h_niceng220er4.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>25 more per 1,000</p>
|
|
<p>(34 fewer to 259 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng220er4.tab13_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng220er4.tab13_2"><p class="no_margin">Downgraded by 1 or 2 increments due to outcome indirectness</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng220er4.tab13_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab14"><div id="niceng220er4.tab14" class="table"><h3><span class="label">Table 14</span><span class="title">Clinical evidence summary: modafinil compared to placebo</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab14/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab14_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab14_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab14_1_1_1_2" style="text-align:left;vertical-align:bottom;">№ of participants (studies) Follow up</th><th id="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab14_1_1_1_3" style="text-align:left;vertical-align:bottom;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab14_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng220er4.tab14_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng220er4.tab14_1_1_1_5" id="hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with placebo</th><th headers="hd_h_niceng220er4.tab14_1_1_1_5" id="hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with modafinil</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (Modified Fatigue Impact Scale Total Score, 0–84, lower values are better, final value, parallel trial and crossover trials) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>549</p>
|
|
<p>(5 RCTs)</p>
|
|
<p>follow up: mean 6 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕◯◯</p>
|
|
<p>LOW<sup>a</sup><sup>,</sup><sup>b</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.23 lower</b>
|
|
</p>
|
|
<p>(2.68 lower to 2.22 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events (crossover trials) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>285</p>
|
|
<p>(2 RCTs)</p>
|
|
<p>follow up: mean 6 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.00</p>
|
|
<p>(0.18 to 5.63)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 per 1,000</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>0 fewer per 1,000</b>
|
|
</p>
|
|
<p>(12 fewer to 65 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardiac events/arrhythmias at 3–6 months (crossover trial)</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>249</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 6 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.65</p>
|
|
<p>(0.40 to 6.77)</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 per 1,000</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>16 more per 1,000</b>
|
|
</p>
|
|
<p>(15 fewer to 140 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (HAQUAMS, scale range unclear, lower values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>121</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 8 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕◯◯</p>
|
|
<p>LOW<sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 11.04</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.45 higher</b>
|
|
</p>
|
|
<p>(0.59 lower to 1.49 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (SF-36 physical component summary, 0–100, higher values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>30</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 40.2</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 1.3 higher</b>
|
|
</p>
|
|
<p>(3.81 lower to 6.41 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (SF-36 mental component summary, 0–100, higher values are better, final value, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>30</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 4 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 40.4</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 2.4 higher</b>
|
|
</p>
|
|
<p>(2.59 lower to 7.39 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (Multiple Sclerosis Quality of Life Inventory - Bodily pain, scale range unclear, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 7.57</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0</b>
|
|
</p>
|
|
<p>(1.89 lower to 1.89 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (Multiple Sclerosis Quality of Life Inventory - Physical functioning, scale range unclear, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕◯</p>
|
|
<p>MODERATE<sup>b</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 15.54</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 6.24 higher</b>
|
|
</p>
|
|
<p>(3.29 higher to 9.19 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (Multiple Sclerosis Quality of Life Inventory - role physical, scale range unclear, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕◯◯</p>
|
|
<p>LOW<sup>a</sup><sup>,</sup><sup>b</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 4.57</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 2.65 higher</b>
|
|
</p>
|
|
<p>(2.12 higher to 3.18 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (Multiple Sclerosis Quality of Life Inventory - vitality scale, scale range unclear, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 12</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 4.11 higher</b>
|
|
</p>
|
|
<p>(0.2 higher to 8.02 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (Multiple Sclerosis Quality of Life Inventory - General health, scale range unclear, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 17.11</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.2 higher</b>
|
|
</p>
|
|
<p>(2.63 lower to 3.03 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health-related Quality of Life (Multiple Sclerosis Quality of Life Inventory - Mental health, scale range unclear, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕◯</p>
|
|
<p>MODERATE<sup>b</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean health-related Quality of Life was 7.57</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 18.54 higher</b>
|
|
</p>
|
|
<p>(16.6 higher to 20.48 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (Digit Vigilance Test total errors, lower values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive function was 5.55</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 1.34 lower</b>
|
|
</p>
|
|
<p>(4.22 lower to 1.54 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (Weschler Adult Intelligence Scale-III Digit Span Total, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive function was 17.25</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.63 lower</b>
|
|
</p>
|
|
<p>(3.76 lower to 2.5 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (Weschler Adult Intelligence Scale-III Letter Number Sequencing, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive function was 11</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.06 lower</b>
|
|
</p>
|
|
<p>(2.35 lower to 2.23 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (symbol digit modalities test, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 51.13</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.32 lower</b>
|
|
</p>
|
|
<p>(9.5 lower to 8.86 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cognitive functions (California Verbal Learning Test - Second Edition, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean cognitive functions was 52.75</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 2.56 lower</b>
|
|
</p>
|
|
<p>(10.9 lower to 5.78 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Psychological symptoms (The State Trait Anxiety Inventory, 0–60, lower values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕◯◯</p>
|
|
<p>LOW<sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean psychological symptoms was 25.56</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 1.5 lower</b>
|
|
</p>
|
|
<p>(6.82 lower to 3.82 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Psychological symptoms (Chicago Multiscale Depression Inventory Total Score, scale range unclear, higher values are better, final value, crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 2 months</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>VERY LOW<sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean psychological symptoms was 67.32</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.37 higher</b>
|
|
</p>
|
|
<p>(12.01 lower to 12.75 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Epworth Sleepiness scale (0–24, lower values are better, final values, parallel trial and crossover trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>368</p>
|
|
<p>(2 RCTs)</p>
|
|
<p>follow up: 7 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕◯</p>
|
|
<p>MODERATE<sup>b</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab14_1_1_1_5 hd_h_niceng220er4.tab14_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.78 lower</b>
|
|
</p>
|
|
<p>(1.62 lower to 0.07 higher)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng220er4.tab14_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng220er4.tab14_2"><p class="no_margin">Downgraded by 1 or 2 increments due to outcome indirectness</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng220er4.tab14_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab15"><div id="niceng220er4.tab15" class="table"><h3><span class="label">Table 15</span><span class="title">Clinical evidence summary: combination of pharmacological therapies (amantadine and aspirin) compared to amantadine</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab15/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab15_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng220er4.tab15_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab15_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng220er4.tab15_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab15_1_1_1_2" style="text-align:left;vertical-align:bottom;">№ of participants (studies) Follow up</th><th id="hd_h_niceng220er4.tab15_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab15_1_1_1_3" style="text-align:left;vertical-align:bottom;">Certainty of the evidence (GRADE)</th><th id="hd_h_niceng220er4.tab15_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng220er4.tab15_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng220er4.tab15_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng220er4.tab15_1_1_1_5" id="hd_h_niceng220er4.tab15_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with amantadine</th><th headers="hd_h_niceng220er4.tab15_1_1_1_5" id="hd_h_niceng220er4.tab15_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with combination of pharmacological therapies (amantadine and aspirin)</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patient-reported outcome measures to assess MS fatigue (FSS score, 1–7, lower values are better, final values, parallel trial) at 3–6 months</td><td headers="hd_h_niceng220er4.tab15_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>45</p>
|
|
<p>(1 RCT)</p>
|
|
<p>follow up: 6 weeks</p>
|
|
</td><td headers="hd_h_niceng220er4.tab15_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕◯</p>
|
|
<p>MODERATE<sup>a</sup></p>
|
|
</td><td headers="hd_h_niceng220er4.tab15_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng220er4.tab15_1_1_1_5 hd_h_niceng220er4.tab15_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean patient-reported outcome measures to assess MS fatigue was 3.96</td><td headers="hd_h_niceng220er4.tab15_1_1_1_5 hd_h_niceng220er4.tab15_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>MD 0.6 lower</b>
|
|
</p>
|
|
<p>(0.89 lower to 0.31 lower)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Explanations</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng220er4.tab15_1"><p class="no_margin">Downgraded by 1 or 2 increments due to outcome indirectness</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng220er4tab16"><div id="niceng220er4.tab16" class="table"><h3><span class="label">Table 16</span><span class="title">Unit cost of drugs for the management of fatigue</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.tab16/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.tab16_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng220er4.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Drug</th><th id="hd_h_niceng220er4.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Daily dose</th><th id="hd_h_niceng220er4.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost per day<sup>(f)</sup></th><th id="hd_h_niceng220er4.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost per month</th><th id="hd_h_niceng220er4.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost per year</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Amantadine (capsule)</td><td headers="hd_h_niceng220er4.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">200–400mg<sup>(a)</sup></td><td headers="hd_h_niceng220er4.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.96-£0.1.92</td><td headers="hd_h_niceng220er4.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£29.19-£53.38</td><td headers="hd_h_niceng220er4.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£350.27-£700.54</td></tr><tr><td headers="hd_h_niceng220er4.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Fluoxetine (tablet)</td><td headers="hd_h_niceng220er4.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20–40mg<sup>(b)</sup></td><td headers="hd_h_niceng220er4.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.04-£0.06</td><td headers="hd_h_niceng220er4.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.14-£1.83</td><td headers="hd_h_niceng220er4.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£13.63-£21.90</td></tr><tr><td headers="hd_h_niceng220er4.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Paroxetine (capsule)</td><td headers="hd_h_niceng220er4.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10–40mg<sup>(c)</sup></td><td headers="hd_h_niceng220er4.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.15-£0.11</td><td headers="hd_h_niceng220er4.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.64-£3.39</td><td headers="hd_h_niceng220er4.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£55.66-£40.64</td></tr><tr><td headers="hd_h_niceng220er4.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Aspirin (tablet)</td><td headers="hd_h_niceng220er4.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75mg<sup>(d)</sup></td><td headers="hd_h_niceng220er4.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.05</td><td headers="hd_h_niceng220er4.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.50</td><td headers="hd_h_niceng220er4.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£17.99</td></tr><tr><td headers="hd_h_niceng220er4.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Modafinil (tablet)</td><td headers="hd_h_niceng220er4.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">200–400mg<sup>(e)</sup></td><td headers="hd_h_niceng220er4.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.22-£0.43</td><td headers="hd_h_niceng220er4.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6.54-£13.08</td><td headers="hd_h_niceng220er4.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£78.48-£156.95</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng220er4.tab16_1"><p class="no_margin">BNF<a class="bibr" href="#niceng220er4.s1.1.ref3" rid="niceng220er4.s1.1.ref3"><sup>3</sup></a>, accessed February 2021. 100 mg daily for 1 week, dose to be taken in the morning, then increased to 100 mg twice daily: maximum 400 mg per day.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng220er4.tab16_2"><p class="no_margin">20mg orally once a day for 4 weeks, then up titrated to 40mg a day<a class="bibr" href="#niceng220er4.s1.1.ref3" rid="niceng220er4.s1.1.ref3"><sup>3</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref6" rid="niceng220er4.s1.1.ref6"><sup>6</sup></a></p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng220er4.tab16_3"><p class="no_margin">10mg daily, up titrated to 20mg/day after 1 week with a maximum dose of 40mg/day in subsequent weeks dependent on symptoms or down-titrated due to adverse events<a class="bibr" href="#niceng220er4.s1.1.ref9" rid="niceng220er4.s1.1.ref9"><sup>9</sup></a>. Note 10mg capsule is more expensive than 20mg tablet.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="niceng220er4.tab16_4"><p class="no_margin">BNF<a class="bibr" href="#niceng220er4.s1.1.ref3" rid="niceng220er4.s1.1.ref3"><sup>3</sup></a>. Accessed 25/02/2021: 75 mg once daily. Oral low dose aspirin (80mg tablets) daily for 8 weeks<a class="bibr" href="#niceng220er4.s1.1.ref22" rid="niceng220er4.s1.1.ref22"><sup>22</sup></a>.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(e)</dt><dd><div id="niceng220er4.tab16_5"><p class="no_margin">200mg daily for 1 month, adjusted according to response to 200–400 mg/day<a class="bibr" href="#niceng220er4.s1.1.ref10" rid="niceng220er4.s1.1.ref10"><sup>10</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref14" rid="niceng220er4.s1.1.ref14"><sup>14</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref15" rid="niceng220er4.s1.1.ref15"><sup>15</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref19" rid="niceng220er4.s1.1.ref19"><sup>19</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng220er4.s1.1.ref26" rid="niceng220er4.s1.1.ref26"><sup>26</sup></a>.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(f)</dt><dd><div id="niceng220er4.tab16_6"><p class="no_margin">BNF<a class="bibr" href="#niceng220er4.s1.1.ref3" rid="niceng220er4.s1.1.ref3"><sup>3</sup></a>. Accessed 25/02/2021</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng220er4appjtab26"><div id="niceng220er4.appj.tab26" class="table"><h3><span class="label">Table 26</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK585274/table/niceng220er4.appj.tab26/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng220er4.appj.tab26_lrgtbl__"><table><thead><tr><th id="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Code [Reason]</th></tr></thead><tbody><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Asano, Miho and Finlayson, Marcia L. (2014) Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Multiple sclerosis international
|
|
2014: 798285 [<a href="/pmc/articles/PMC4052049/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4052049</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24963407" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24963407</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bazzari, F. H. (2018) Available pharmacological options and symptomatic treatments of multiple sclerosis. Systematic Reviews in Pharmacy
|
|
9(1): 17–21
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Cameron, M., Cohen, J., Miller, A.
|
|
et al (2019) Inroads: A phase 3 study to assess the efficacy and safety of ADS-5102 (Amantadine) extended-release capsules in multiple sclerosis (MS) patients with walking impairment. Neurology
|
|
92(15
|
|
Suppl 1)
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Conference abstract</p>
|
|
<p>- Full text paper not available</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Chataway, J., De Angelis, F., Connick, P.
|
|
et al (2018) MS-SMART Trial: A multi-arm phase 2b randomised double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [NCT01910259]. Multiple Sclerosis Journal
|
|
24(2 Suppl): 986–987
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Chen, M. H., Goverover, Y., Genova, H. M.
|
|
et al (2020) Cognitive efficacy of pharmacologic treatments in multiple sclerosis: A systematic review. CNS Drugs
|
|
34(6): 599–628 [<a href="/pmc/articles/PMC7275014/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7275014</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32361940" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32361940</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Cohen, J. A., Gudesblatt, M., Hunter, S. F.
|
|
et al (2017) A phase 2 study of ADS-5102 (amantadine hydrochloride) extended-release capsules in multiple sclerosis patients with walking impairment. Multiple Sclerosis
|
|
23(Suppl 1): 22–23
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Cotter, J., Muhlert, N., Talwar, A.
|
|
et al (2018) Examining the effectiveness of acetylcholinesterase inhibitors and stimulant-based medications for cognitive dysfunction in multiple sclerosis: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews
|
|
86: 99–107 [<a href="https://pubmed.ncbi.nlm.nih.gov/29406017" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29406017</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Filippi, M., Valsasina, P., Colombo, B.
|
|
et al (2015) Fampridine modulates thalamic resting state functional connectivity and ameliorates fatigue in multiple sclerosis patients. Multiple Sclerosis
|
|
23(11
|
|
Suppl1): 331–332
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Khan, F.; Amatya, B.; Galea, M. (2014) Management of fatigue in persons with multiple sclerosis. Frontiers in Neurology
|
|
5: 177 [<a href="/pmc/articles/PMC4163985/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4163985</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25309504" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25309504</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study does not contain an intervention relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kratz, Anna L., Alschuler, Kevin N., Ehde, Dawn M.
|
|
et al (2019) A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: The design of the “COMBO-MS” trial. Contemporary clinical trials
|
|
84: 105821 [<a href="https://pubmed.ncbi.nlm.nih.gov/31400515" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31400515</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Data not reported in an extractable format or a format that can be analysed</p>
|
|
<p>
|
|
<i>Protocol only</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lange
|
|
R, Volkmer
|
|
M, Heesen
|
|
C
|
|
et al (2009) Modafinil effects in multiple sclerosis patients with fatigue. Journal of neurology
|
|
256(4): 645–650 [<a href="https://pubmed.ncbi.nlm.nih.gov/19367356" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19367356</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Data not reported in an extractable format or a format that can be analysed</p>
|
|
<p>- Not a peer-reviewed publication</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Leavitt, V. M., Blanchard, A. R., Guo, C. Y.
|
|
et al (2017) Aspirin improves exercise endurance in multiple sclerosis: Pilot findings from a double-blind randomized placebocontrolled crossover trial. Multiple Sclerosis Journal
|
|
23(3
|
|
Suppl 1): 413–414
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Leavitt, V. M., Blanchard, A. R., Guo, C. Y.
|
|
et al (2018) Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial. Multiple Sclerosis Journal
|
|
24(11): 1511–1513 [<a href="https://pubmed.ncbi.nlm.nih.gov/29076760" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29076760</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>Inadequate washout period</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Leavitt, V., Blanchard, A., Guo, C. Y.
|
|
et al (2018) A randomized controlled pilot trial of aspirin to improve exercise performance in persons with multiple sclerosis. Neurology
|
|
90(15
|
|
Suppl 1)
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Conference abstract</p>
|
|
<p>- Full text paper not available</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Miller, Philippa and Soundy, Andrew (2017) The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis. Journal of the neurological sciences
|
|
381: 41–54 [<a href="https://pubmed.ncbi.nlm.nih.gov/28991714" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28991714</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study design not relevant to this review protocol</p>
|
|
<p>
|
|
<i>Systematic review of systematic reviews</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Nourbakhsh, B., Revirajan, N., Morris, B.
|
|
et al (2019) Phase 3 randomized, controlled trial of methylphenidate, modafinil and amantadine for MS fatigue (TRIUMPHANTMS): Baseline data. Multiple Sclerosis Journal
|
|
25(Suppl 2): 794–795
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Nourbakhsh, B.; Revirajan, N.; Waubant, E. (2017) Study design for a pragmatic clinical trial of fatigue medications in multiple sclerosis. Neurology
|
|
88(16
|
|
Suppl 1)
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Conference abstract</p>
|
|
<p>- Full text paper not available</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Payne, C.; Wiffen, P. J.; Martin, S. (2017) Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database of Systematic Reviews
|
|
2017(4): cd008427 [<a href="https://pubmed.ncbi.nlm.nih.gov/22258985" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22258985</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Full text paper not available</p>
|
|
<p>
|
|
<i>Withdrawn due to the update not meeting the timelines and expectations of Cochrane and the PaPaS review group</i>
|
|
</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Perez, Dominique Q.; Espiritu, Adrian I.; Jamora, Roland Dominic G. (2020) Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis. Neurodegenerative disease management
|
|
10(6): 383–395 [<a href="https://pubmed.ncbi.nlm.nih.gov/33012266" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33012266</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Poulsen, M., Damgaard, B., Zerahn, B.
|
|
et al (2015) Feasibility of treatment with modafinil to reduce fatigue after stroke. International Journal of Stroke
|
|
10(Suppl 2): 92
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rejdak, Konrad and Grieb, Pawel (2020) Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Multiple sclerosis and related disorders
|
|
42: 102163 [<a href="/pmc/articles/PMC7190496/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7190496</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32388458" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32388458</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rocca, M. A., Valsasina, P., Colombo, B.
|
|
et al (2018) Modulation of cortico-subcortical functional connectivity occurs after symptomatic treatment of fatigue in patients with multiple sclerosis. Multiple Sclerosis Journal
|
|
24(Suppl 2): 317–318
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rosenberg, G. A. and Appenzeller, O. (1988) Amantadine, fatigue, and multiple sclerosis. Archives of neurology
|
|
45(10): 1104–1106 [<a href="https://pubmed.ncbi.nlm.nih.gov/2972270" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2972270</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Primary study from before the date limitation which is unlikely to add extra information that will impact the results of the review</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sailer, M., Heinze, H. J., Schoenfeld, M. A.
|
|
et al (2000) Amantadine influences cognitive processing in patients with multiple sclerosis. Pharmacopsychiatry
|
|
33(1): 28–37 [<a href="https://pubmed.ncbi.nlm.nih.gov/10721881" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10721881</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study reported outcomes not included in the protocol (electrophysiological parameters)</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Santarnecchi, Emiliano, Rossi, Simone, Bartalini, Sabina
|
|
et al (2015) Neurophysiological correlates of central fatigue in healthy subjects and multiple sclerosis patients before and after treatment with amantadine. Neural Plasticity
|
|
2015: 616242 [<a href="/pmc/articles/PMC4506817/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4506817</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26236509" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26236509</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Shangyan, Hei, Kuiqing, Li, Yumin, Xu
|
|
et al (2018) Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. Multiple sclerosis and Related Disorders
|
|
19: 85–89 [<a href="https://pubmed.ncbi.nlm.nih.gov/29175676" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29175676</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Tsou, A., Treadwell, J., Erinoff, E.
|
|
et al (2019) Which treatments improve fatigue and quality of life in Multiple Sclerosis?
|
|
Evidence appraisal and development of visual interactive evidence maps. Neurology
|
|
92(15
|
|
Suppl 1)
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Conference abstract</p>
|
|
<p>- Full text paper not available</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Tur, Carmen (2016) Fatigue management in multiple sclerosis. Current Treatment Options in Neurology
|
|
18(6): 26 [<a href="/pmc/articles/PMC4834309/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4834309</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27087457" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27087457</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wingerchuk, D., Keegan, M., Shuster, E.
|
|
et al (2014) Aspirin is unlikely to have a clinically meaningful effect on multiple sclerosis-related fatigue: Data from a randomized controlled trial. Neurology
|
|
82(10
|
|
Suppl 1)
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Conference abstract</p>
|
|
<p>- Full text paper not available</p>
|
|
</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wu, S., Kutlubaev, M. A., Chun, H. Y. Y.
|
|
et al (2015) Interventions for post-stroke fatigue. Cochrane Database of Systematic Reviews [<a href="/pmc/articles/PMC7387276/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7387276</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26133313" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26133313</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Yang, Ting-Ting, Wang, Li, Deng, Xiao-Yang
|
|
et al (2017) Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. Journal of the neurological sciences
|
|
380: 256–261 [<a href="https://pubmed.ncbi.nlm.nih.gov/28870581" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28870581</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Zielinska-Nowak, E., Wlodarczyk, L., Kostka, J.
|
|
et al (2020) New strategies for rehabilitation and pharmacological treatment of fatigue syndrome in multiple sclerosis. Journal of Clinical Medicine
|
|
9(11): 1–18 [<a href="/pmc/articles/PMC7695014/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7695014</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33171768" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33171768</span></a>]
|
|
</td><td headers="hd_h_niceng220er4.appj.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|